CUMULATIVE SUPPLEMENT 6
JAN'96-JUN'96



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

16TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT
DIVISION OF DRUG INFORMATION RESOURCES

1996

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

16TH EDITION

Cumulative Supplement 6

JUNE 1996

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

16TH EDITION

CUMULATIVE SUPPLEMENT 6
JUNE 1996

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 16th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line containing shaded print. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the shaded print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 16th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 17th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval

on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release;transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.3 CHANGE OF A THERAPEUTIC EQUIVALENT CODE FOR A DRUG ENTITY

Propantheline Bromide

In Cumulative Supplement 1 of the *Approved Drug Products with Therapeutic Equivalence Evaluations*, 16th Edition, (Orange Book), the Agency proposed to change the therapeutic equivalence code for propantheline bromide oral tablets from a drug product not presenting a bioequivalence problem **(AA)** to a drug product with a potential bioequivalence problem **(BP)**.

The Agency solicited comments from interested persons to be received no later than 60 days from the first day of the month following the publication of Cumulative Supplement 1. The proposal did not elicit any comments from the readers. In addition, the two firms who hold an active ANDA and are marketing the drug product were contacted to inform them that the codes for their propantheline drug products were going to be changed. Since there were no comments submitted by the readers or by the two firms who hold an active ANDA, the therapeutic equivalence code for propantheline bromide tablets will be changed to one reflecting a potential bioequivalence problem. Therefore, all oral propantheline bromide tablets will be changed in this month's Cumulative Supplement from **(AA)** to **(BP)** to reflect it has a potential for a bioequivalence problem.

An acceptable *in vivo* bioequivalence study, among other information, will be required to change the code from **(BP)** to **(AB)** for an already approved ANDA listed in the Orange Book. Any ANDA submission must contain an acceptable *in vivo* bioequivalence study for filing purposes.

1.4 REFERENCE LISTED DRUG

A reference listed drug (21 CFR 314.94(a)(3) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.

FDA has identified in the Prescription Drug Product and OTC Drug Product Lists those reference listed drugs to which the *in vivo* bioequivalence and, in some instances, the *in vitro* bioequivalence of the applicant's product is compared. By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. Such variations could result if generic drugs were compared to different reference listed drugs. However, in some instances when multiple NDAs are approved for a single drug product, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. A firm wishing to market a generic version of an NDA listed drug that is not designated as the reference listed may petition the Agency through the Citizen Petition procedure (see 21 CFR 10.25(a) and CFR 10.30). When the Citizen Petition is approved, the second NDA will be designated as an additional reference listed drug and the petitioner may submit an Abbreviated New Drug Application citing the designated reference listed drug. Section 1.7, *Therapeutic Equivalence Evaluations Codes* of the *Introduction* to the *Approved Drug Products with Therapeutic Equivalence Evaluations* publication explains the coding system for multisource drug products listed under the same heading with two reference listed drugs.

The concept of having only one reference listed drug was intended to apply to drug products in which bioequivalence is demonstrated through *in vivo* methodology. It was not intended to apply to two NDA drug products in which the *in vivo* determination of bioequivalence is self evident and a waiver of *in vivo* bioequivalence is granted by the agency. These types of drug products are assigned therapeutic equivalence codes, e.g., of **AN**, **AT**, **AA**. Therefore, drug products that do not represent a bioequivalence problem with two or more NDAs will have the reference listed drug designation assigned to each NDA.

The reference listed drug is identified by the symbol " + " in the Prescription Drug Product List. These identified reference listed drugs represent the best judgement of the Division of Bioequivalence at this time. The prescription Drug Product List identifies reference drugs for oral dosage forms, injectables, ophthalmics, otics, and topical products. It is recommended that a firm planning to conduct an *in vivo* bioequivalence study, or planning to manufacture a batch of a drug product for which an *in vivo* waiver of bioequivalence will be requested, contact the Division of Bioequivalence, OFFICE OF GENERIC DRUGS, to confirm the appropriate reference listed drug.

1.5 COURT ORDER REGARDING ABBOTT U.S. PATENT NO. 4112097, (TERAZOSIN HCL)

On April 9, 1996, the United States District Court for the Northern District of Illinois (Eastern Division) issued an order in the case of Abbott Labs v. Geneva Pharmaceuticals, Inc., directing Abbott to remove U.S. Patent No. 4112097 from the Orange Book. To comply with that order, Abbott has requested that FDA remove patent 4112097 from the Orange Book. The FDA complied with this request in the March 1996 cumulative supplement. On April 9, 1996, Abbott appealed the district court's decision to the U.S. Court of Appeals for the Federal Circuit.

1.6 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name

changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
1ST TEXAS PHARMACEUTICALS INC SUB SCHERER LABORATORIES (1ST TX)	SCHERER LABORATORIES, INC (SCHERER)
BOEHRINGER MANNHEIM PHARMACEUTICALS CORP (BOEHRINGER MANNHEIM)	BOEHRINGER MANNHEIM CORPORATION THERAPEUTICS DIVISION (BOEHRINGER MANNHEIM)
DAVID BULL LABORATORIES PARTY LTD (BULL D)	FH FAULDING AND CO LTD (FAULDING) **THEN CHANGED TO** FAULDING PHARMACEUTICAL CO (FAULDING)
HOECHST ROUSSEL PHARMACEUTICALS INC (HOECHST ROUSSEL)	HOECHST MARION ROUSSEL INC (HOECHST MARION RSSL)
PHARMACIA INC (PHARMACIA)	PHARMACIA AND UPJOHN CO (PHARMACIA AND UPJOHN)
SCHWARZ PHARMA KREMERS URBAN CO SUB SCHWARZ PHARMA AG (SPKU)	SCHWARZ PHARMA INC (SCHWARZ PHARMA)
UPJOHN CO (UPJOHN)	PHARMACIA AND UPJOHN CO (PHARMACIA AND UPJOHN)

1.7 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is now available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

The following *Approved Drug Products with Therapeutic Equivalence Evaluations* files are now available on Internet and are updated each October and April: Prescription Drug Product List; OTC Drug Products; Discontinued Drug Products; and Appendices. The update in October will include drug products that have been approved through August and the update in April will include drug products that have been approved through December.

These files may be accessed on the Internet's World Wide Web. FDA's Internet site replaces the Agency's electronic bulletin board and offers more information, in a more user-friendly form. To access the FDA Home Page, use this Uniform Resource Locator (URL): http://www.fda.gov. You do not need an Internet connection to reach the FDA Home Page; you can use the free dial-up connection (800) 222-0185. For further assistance, please call (301) 443-4908.

The Prescription Drug Products and OTC Drug Product files will be available on a monthly basis in the near future.

1.8 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1995) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1995	MAR 1996	JUN 1996	SEP 1996
DRUG PRODUCTS LISTED	9286	9303	9384	
SINGLE SOURCE	2217 (23.9%)	2248 (24.2%)	2323 (24.8%)	
MULTISOURCE	7069 (76.1%)	7055 (75.8%)	7061 (75.2%)	
THERAPEUTICALLY EQUIVALENT	6437 (69.3%)	6425 (69.0%)	6490 (69.2%)	
NOT THERAPEUTICALLY EQUIVALENT	440 (4.7%)	443 (4.8%)	468 (5.0%)	
EXCEPTIONS[1]	192 (2.1%)	187 (2.0%)	103 (1.0%)	
NEW MOLECULAR ENTITIES APPROVED	--	6	15	
NUMBER OF APPLICANTS	586	592	621	

[1]Amino acid-containing products of varying composition (see Introduction, page xvi of the List).

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

	ESGIC-PLUS			
	+	MIKART	500MG;50MG;40MG	N40085 001 MAR 28, 1996

TABLET; ORAL

	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE			
		MIKART	500MG;50MG;40MG	N89451 001 MAY 23, 1988
	+		500MG;50MG;40MG	N89451 001 MAY 23, 1988

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

		DHC PLUS			
> DLT >	AA	PURDUE FREDERICK	356.4MG;30MG;16MG	N88584 001 MAR 04, 1986
> DLT >				
> ADD >	+		356.4MG;30MG;16MG	N88584 001 MAR 04, 1986
> ADD >				
> DLT >		SYNALGOS-DC-A		
> DLT >	AA +	WYETH AYERST	356.4MG;30MG;16MG	N89166 001 MAY 14, 1986
> DLT >				
> ADD >	@		356.4MG;30MG;16MG	N89166 001 MAY 14, 1986
> ADD >				

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

	ACETAMINOPHEN AND CODEINE PHOSPHATE			
AA		HI TECH PHARMA	120MG/5ML;12MG/5ML	N40119 001 APR 26, 1996
	TYLENOL W/ CODEINE			
AA		JOHNSON RW	120MG/5ML;12MG/5ML	N85057 001
AA	+		120MG/5ML;12MG/5ML	N85057 001

TABLET; ORAL

	ACETAMINOPHEN AND CODEINE PHOSPHATE			
AA		GENEVA PHARMS	300MG;30MG	N85291 002
AA			300MG;60MG	N85964 001
	@		300MG;30MG	N85291 002
	@		300MG;60MG	N85964 001
AA		HALSEY	300MG;60MG	N86549 001
	@		300MG;60MG	N86549 001

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

	ACETAMINOPHEN AND CODEINE PHOSPHATE			
AA		MIKART	300MG;30MG	N89238 001 FEB 25, 1986
AA			300MG;60MG	N89244 001 FEB 25, 1986
	@		300MG;60MG	N89244 001 FEB 25, 1986
	ACETAMINOPHEN AND CODEINE PHOSPHATE #3			
AA		MIKART	300MG;30MG	N89238 001 FEB 25, 1986
AA		SUPERPHARM	300MG;30MG	N89184 001 OCT 18, 1985
	@		300MG;30MG	N89184 001 OCT 18, 1985
	ACETAMINOPHEN AND CODEINE PHOSPHATE #4			
AA		SUPERPHARM	300MG;60MG	N89185 001 OCT 18, 1985
	@		300MG;60MG	N89185 001 OCT 18, 1985
	ACETAMINOPHEN W/ CODEINE PHOSPHATE			
AA		HALSEY	300MG;15MG	N83871 001
AA			300MG;30MG	N83872 001
	@		300MG;15MG	N83871 001
	@		300MG;30MG	N83872 001

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

	ANEXSIA			
AA		KING PHARMS	500MG;5MG	N89160 001 APR 23, 1987
AA		MALLINCKRODT	500MG;5MG	N89160 001 APR 23, 1987
	ANEXSIA 7.5/650			
AA		KING PHARMS	650MG;7.5MG	N89725 001 SEP 30, 1987
AA		MALLINCKRODT	650MG;7.5MG	N89725 001 SEP 30, 1987
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA		ROYCE LABS	500MG;2.5MG	N40123 003 MAR 04, 1996
AA			500MG;5MG	N40122 001 MAR 04, 1996
AA			500MG;7.5MG	N40123 004 MAR 04, 1996

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	ROYCE LABS	650MG;7.5MG	N40123 001 MAR 04, 1996		
AA		650MG;10MG	N40123 002 MAR 04, 1996		
AA		750MG;7.5MG	N40122 002 MAR 04, 1996		
AA	VINTAGE PHARMS	500MG;7.5MG	N40144 001 FEB 22, 1996		
AA		650MG;10MG	N40143 001 FEB 22, 1996	> DLT >	
AA		750MG;7.5MG	N40157 001 APR 12, 1996	> ADD >	
	LORTAB				
	UCB	500MG;10MG	N40100 001 JAN 26, 1996	> DLT >	
	+	500MG;10MG	N40100 001 JAN 26, 1996	> ADD >	

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

AB	SUPERPHARM	650MG;100MG	N71319 001 JAN 06, 1987		
	@	650MG;100MG	N71319 001 JAN 06, 1987		

ADAPALENE

GEL; TOPICAL
DIFFERIN

	+ GALDERMA	0.1%	N20380 001 MAY 31, 1996		

SOLUTION; TOPICAL
DIFFERIN

	+ GALDERMA	0.1%	N20338 001 MAY 31, 1996	> ADD >	

ALBENDAZOLE

TABLET; ORAL
ALBENZA

	+ SMITHKLINE BEECHAM	200MG	N20666 001 JUN 11, 1996		

ALBUTEROL SULFATE

SOLUTION; INHALATION
VENTOLIN

AN	GLAXO WELLCOME	EQ 0.083% BASE	N19773 001 APR 23, 1992		
AN	+	EQ 0.083% BASE	N19773 001 APR 23, 1992		
AN		EQ 0.5% BASE	N19269 002 JAN 16, 1987		
AN	+	EQ 0.5% BASE	N19269 002 JAN 16, 1987		

SYRUP; ORAL
PROVENTIL

AA	SCHERING	EQ 2MG BASE/5ML	N18062 001 JAN 19, 1983		
AA	+	EQ 2MG BASE/5ML	N18062 001 JAN 19, 1983		

ALLOPURINOL SODIUM

INJECTABLE; INJECTION
ZYLOPRIM

	+ GLAXO WELLCOME	EQ 500MG BASE/VIAL	N20298 001 MAY 17, 1996		

ALPROSTADIL

INJECTABLE; INJECTION
CAVERJECT

	PHARMACIA AND UPJOHN	0.005MG/VIAL	N20379 003 JUN 27, 1996	> ADD >	

AMINO ACIDS

INJECTABLE; INJECTION

	AMINOSYN-HF 8%			
	ABBOTT	8%	N20345 001	APR 04, 1996
	HEPATASOL 8%			
	BAXTER	8%	N20360 001	APR 04, 1996

AMINOPHYLLINE

TABLET; ORAL

	AMINOPHYLLINE			
@	PHOENIX LABS NY	100MG	N85409 001	
@		200MG	N85410 001	
@	VINTAGE PHARMS	100MG	N85409 001	
@		200MG	N85410 001	

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

	AMITRIPTYLINE HCL			
BP	HALSEY	25MG	N85922 001	
@		25MG	N85922 001	
	ENDEP			
AB	ROCHE	150MG	N85303 001	
@		150MG	N85303 001	

AMOXICILLIN

TABLET, CHEWABLE; ORAL

	AMOXICILLIN			
AB	APOTHECON	125MG	N64131 001	MAY 06, 1996
AB		250MG	N64131 002	MAY 06, 1996
AB	CLONMEL HLTH CARE	125MG	N64139 001	JAN 29, 1996
AB		250MG	N64139 002	JAN 29, 1996

AMOXICILLIN; CLAVULANATE POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

	AUGMENTIN '200'			
+	SMITHKLINE BEECHAM	200MG/5ML; EQ 28.5MG BASE/5ML	N50725 001	MAY 31, 1996
	AUGMENTIN '400'			
+	SMITHKLINE BEECHAM	400MG/5ML; EQ 57MG BASE/5ML	N50725 002	MAY 31, 1996

TABLET; ORAL

	AUGMENTIN '875'			
+	SMITHKLINE BEECHAM	875MG;EQ 125MG BASE	N50720 001	FEB 13, 1996

TABLET, CHEWABLE; ORAL

	AUGMENTIN '200'			
+	SMITHKLINE BEECHAM	200MG;EQ 28.5MG BASE	N50726 001	MAY 31, 1996
	AUGMENTIN '400'			
+	SMITHKLINE BEECHAM	400MG;EQ 57MG BASE	N50726 002	MAY 31, 1996

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

	ADDERALL 10			
	RICHWOOD PHARM	2.5MG;2.5MG;2.5MG;2.5MG	N11522 007	FEB 13, 1996
	ADDERALL 20			
+	RICHWOOD PHARM	5MG;5MG;5MG;5MG	N11522 008	FEB 13, 1996

AMPHOTERICIN B

SUSPENSION; ORAL

	FUNGIZONE		
+	BRISTOL MYERS SQUIBB	100MG/ML	N50341 003

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

POWDER FOR RECONSTITUTION; ORAL

	POLYCILLIN-PRB			
AB	+ APOTHECON	EQ 3.5GM BASE/BOT;1GM/BOT	N61898 001	

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

POWDER FOR RECONSTITUTION; ORAL

	POLYCILLIN-PRB			
	@ APOTHECON	EQ 3.5GM BASE/BOT;1GM/BOT		N61898 001
	PROBAMPACIN			
AB	BIOCRAFT	**EQ 3.5GM BASE/BOT;1GM/BOT**		**N61741 001**
+		EQ 3.5GM BASE/BOT;1GM/BOT		N61741 001

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

	BUTALBITAL, ASPIRIN & CAFFEINE			
AB	HALSEY	**325MG;50MG;40MG**		**N89448 001**
				DEC 01, 1986
	@	325MG;50MG;40MG		N89448 001
				DEC 01, 1986

ASPIRIN; CARISOPRODOL

TABLET; ORAL

	CARISOPRODOL AND ASPIRIN			
AB	EON LABS	**325MG;200MG**		**N40116 001**
				APR 25, 1996

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

	CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE			
AB	EON LABS	**325MG;200MG;16MG**		**N40118 001**
				APR 16, 1996
	SOMA COMPOUND W/ CODEINE			
AB +	WALLACE PHARMS	**325MG;200MG;16MG**		**N12366 002**
				JUL 11, 1983

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

	LOGEN			
AA	SUPERPHARM	**0.025MG;2.5MG**		**N88962 001**
				MAY 10, 1985
	@	0.025MG;2.5MG		N88962 001
				MAY 10, 1985
	LOW-QUEL			
AA	HALSEY	**0.025MG;2.5MG**		**N85211 001**

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

	LOW-QUEL			
	@ HALSEY	0.025MG;2.5MG		N85211 001

AZATHIOPRINE

TABLET; ORAL

	AZATHIOPRINE			
AB	ROXANE	**50MG**		**N74069 001**
				FEB 16, 1996
	IMURAN			
AB +	GLAXO WELLCOME	**50MG**		**N16324 001**

AZITHROMYCIN DIHYDRATE

TABLET; ORAL

>ADD>	ZITHROMAX			
>ADD>	+ PFIZER	EQ 600MG BASE		N50730 001
>ADD>				JUN 12, 1996

BACITRACIN

OINTMENT; OPHTHALMIC

	BACITRACIN			
AT	ALTANA	**500 UNITS/GM**		**N61212 001**
+		500 UNITS/GM		N61212 001
AT +	LILLY	**500 UNITS/GM**		**N60687 001**
@		500 UNITS/GM		N60687 001

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

	BECONASE AQ			
>DLT> **BN** +	**GLAXO WELLCOME**	**EQ 0.042MG DIPROP/INH**		**N19389 001**
>DLT>				**JUL 27, 1987**
>ADD> BN		EQ 0.042MG DIPROP/INH		N19389 001
>ADD>				JUL 27, 1987
	VANCENASE AQ			
>DLT> **BN**	**SCHERING**	**EQ 0.042MG DIPROP/INH**		**N19589 001**
>DLT>				**DEC 23, 1987**
>ADD> BN +		EQ 0.042MG DIPROP/INH		N19589 001
>ADD>				DEC 23, 1987

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL
VANCENASE AQ
> ADD > + SCHERING EQ 0.084MG DIPROP/INH N20469 001
> ADD > JUN 26, 1996

BLEOMYCIN SULFATE

INJECTABLE; INJECTION
BLENOXANE
> ADD > AP + BRISTOL MYERS SQUIBB EQ 15 UNITS BASE/VIAL N50443 001
> DLT > + EQ 15 UNITS BASE/VIAL N50443 001
> ADD > BLEOMYCIN SULFATE
> ADD > AP PHARMACIA EQ 15 UNITS BASE/VIAL N64084 001
> ADD > JUN 01, 1996
> ADD > + EQ 30 UNITS BASE/VIAL N64084 002
> ADD > JUN 01, 1996

BROMPHENIRAMINE MALEATE

TABLET; ORAL
DIMETANE
AA + ROBINS AH 4MG N10799 003
@ WHITEHALL ROBINS 4MG N10799 003

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPRENEX
> ADD > AP + RECKITT AND COLMAN EQ 0.3MG BASE/ML N18401 001
> ADD > BUPRENORPHINE HCL
> ADD > AP SANOFI WINTHROP EQ 0.3MG BASE/ML N74137 001
> ADD > JUN 03, 1996

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL
BUSPAR
+ BRISTOL MYERS SQUIBB 10MG N18731 002
SEP 29, 1986
10MG N18731 002
SEP 29, 1986
+ 15MG N18731 003
APR 22, 1996

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL
BUSPAR
@ BRISTOL MYERS SQUIBB 30MG N18731 004
APR 22, 1996

BUTABARBITAL SODIUM

ELIXIR; ORAL
SARISOL
AA HALSEY 30MG/5ML N84723 001
@ 30MG/5ML N84723 001

TABLET; ORAL
SARISOL NO. 1
AA HALSEY 15MG N84719 001
@ 15MG N84719 001
SARISOL NO. 2
AA HALSEY 30MG N84719 002
@ 30MG N84719 002

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
AT FRESENIUS 25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML N18379 002
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
AT FRESENIUS 25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML N18379 003
DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER
AT FRESENIUS 25.7MG/100ML;3.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML N18379 007
JUN 24, 1988
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
AT FRESENIUS 25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML N18379 001

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N18379 004 JUL 07, 1982

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N18379 005 JUL 07, 1982

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N18379 008 JUN 24, 1988

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N18379 006 JUL 07, 1982

INPERSOL W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;1.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML	N18379 002

INPERSOL W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;2.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML	N18379 003

INPERSOL W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;3.5GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML	N18379 007 JUN 24, 1988

INPERSOL W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;4.25GM/100ML; 15.2MG/100ML;567MG/100ML; 392MG/100ML	N18379 001

INPERSOL-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;1.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N18379 004 JUL 07, 1982

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;2.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N18379 005 JUL 07, 1982

INPERSOL-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;3.5GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N18379 008 JUN 24, 1988

INPERSOL-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	FRESENIUS	25.7MG/100ML;4.25GM/100ML; 5.08MG/100ML;538MG/100ML; 448MG/100ML	N18379 006 JUL 07, 1982

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	BIOCRAFT	12.5MG	N74433 001 FEB 13, 1996
AB		25MG	N74433 002 FEB 13, 1996
AB		50MG	N74433 003 FEB 13, 1996
AB		100MG	N74433 004 FEB 13, 1996
AB	CHELSEA LABS	12.5MG	N74576 001 APR 23, 1996
AB		25MG	N74576 002 APR 23, 1996
AB		50MG	N74576 003 APR 23, 1996
AB		100MG	N74576 004 APR 23, 1996
AB	COPLEY PHARM	12.5MG	N74462 001 FEB 13, 1996
AB		25MG	N74462 002 FEB 13, 1996
AB		50MG	N74462 003 FEB 13, 1996
AB		100MG	N74462 004 FEB 13, 1996

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB	DANBURY PHARMA	12.5MG	N74386 001	MAY 23, 1996
AB		25MG	N74386 002	MAY 23, 1996
AB		50MG	N74386 003	MAY 23, 1996
AB		100MG	N74386 004	MAY 23, 1996
AB	ENDO LABS	12.5MG	N74418 001	FEB 13, 1996
AB		25MG	N74418 002	FEB 13, 1996
AB		50MG	N74418 003	FEB 13, 1996
AB		100MG	N74418 004	FEB 13, 1996
AB	EON LABS	12.5MG	N74519 001	FEB 13, 1996
AB		25MG	N74519 002	FEB 13, 1996
AB		50MG	N74519 003	FEB 13, 1996
AB		100MG	N74519 004	FEB 13, 1996
AB	HALLMARK PHARMS	12.5MG	N74477 001	FEB 13, 1996
AB		25MG	N74477 002	FEB 13, 1996
AB		50MG	N74477 003	FEB 13, 1996
AB		100MG	N74477 004	FEB 13, 1996
AB	INVAMED	12.5MG	N74481 001	FEB 13, 1996
AB		25MG	N74481 002	FEB 13, 1996
AB		50MG	N74481 003	FEB 13, 1996
AB		100MG	N74481 004	FEB 13, 1996
AB	LEMMON	12.5MG	N74483 001	FEB 13, 1996
AB		25MG	N74483 002	FEB 13, 1996

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB	LEMMON	50MG	N74483 003	FEB 13, 1996
AB		100MG	N74483 004	FEB 13, 1996
AB	MOVA	12.5MG	N74423 001	FEB 13, 1996
AB		25MG	N74423 002	FEB 13, 1996
AB		50MG	N74423 003	FEB 13, 1996
AB		100MG	N74423 004	FEB 13, 1996
AB	MYLAN	12.5MG	N74434 001	FEB 13, 1996
AB		25MG	N74434 002	FEB 13, 1996
AB		50MG	N74434 003	FEB 13, 1996
AB		100MG	N74434 004	FEB 13, 1996
AB	NOVOPHARM	12.5MG	N74322 001	FEB 13, 1996
AB		25MG	N74322 002	FEB 13, 1996
AB		50MG	N74322 003	FEB 13, 1996
AB		100MG	N74322 004	FEB 13, 1996
AB	PAR PHARM	12.5MG	N74493 001	FEB 13, 1996
AB		25MG	N74493 002	FEB 13, 1996
AB		50MG	N74493 003	FEB 13, 1996
AB		100MG	N74493 004	FEB 13, 1996
AB	ROYCE LABS	12.5MG	N74451 001	FEB 13, 1996
AB		25MG	N74451 002	FEB 13, 1996
AB		50MG	N74451 003	FEB 13, 1996
AB		100MG	N74451 004	FEB 13, 1996

CAPTOPRIL

TABLET; ORAL
CAPTOPRIL

AB	WESTWARD PHARM	12.5MG	N74505 001 FEB 13, 1996	> ADD >	
AB		25MG	N74505 002 FEB 13, 1996	> ADD >	
AB		50MG	N74505 003 FEB 13, 1996	> ADD >	
AB		100MG	N74505 004 FEB 13, 1996	> ADD >	

CARBAMAZEPINE

TABLET, EXTENDED RELEASE; ORAL
TEGRETOL-XR

+	CIBA GEIGY	100MG	N20234 001 MAR 25, 1996	
+		200MG	N20234 002 MAR 25, 1996	
+		400MG	N20234 003 MAR 25, 1996	

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

AA	WEST WARD PHARM	350MG	N40124 001 JAN 24, 1996	

CEFACLOR

CAPSULE; ORAL
CEFACLOR

AB	MARSAM	EQ 250MG BASE	N64148 001 MAY 23, 1996	> DLT >	> DLT >
AB		EQ 500MG BASE	N64148 002 MAY 23, 1996	> ADD >	> ADD >
> ADD > AB	NOVOPHARM	EQ 250MG BASE	N64145 001 JUN 24, 1996	> ADD >	> ADD >
> ADD > AB		EQ 500MG BASE	N64145 002 JUN 24, 1996	> ADD >	> ADD >

> ADD > TABLET, EXTENDED RELEASE; ORAL
> ADD > CECLOR CD
> ADD > + LILLY EQ 375MG BASE N50673 001 JUN 28, 1996 > DLT > > DLT >
> ADD >

> ADD > TABLET, EXTENDED RELEASE; ORAL
> ADD > CECLOR CD
> ADD > + LILLY EQ 500MG BASE N50673 002 JUN 28, 1996
> ADD >

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER

+	BAXTER	EQ 10MG BASE/ML	N50566 003 JUN 08, 1983
+		EQ 20MG BASE/ML	N50566 004 JUN 08, 1983
@		EQ 10MG BASE/ML	N50566 003 JUN 08, 1983
@		EQ 20MG BASE/ML	N50566 004 JUN 08, 1983

CEFEPIME HYDROCHLORIDE (ARGININE FORMULATION)

INJECTABLE; INJECTION
MAXIPIME

+	BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N50679 001 JAN 18, 1996
+		EQ 1GM BASE/VIAL	N50679 002 JAN 18, 1996
+		EQ 2GM BASE/VIAL	N50679 003 JAN 18, 1996

CEFTAZIDIME (ARGININE FORMULATION)

INJECTABLE; INJECTION
CEPTAZ

+	GLAXO WELLCOME	500MG/VIAL	N50646 001 SEP 27, 1990
@		500MG/VIAL	N50646 001 SEP 27, 1990

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

AP	BAXTER	EQ 10MG BASE/ML	N63221 001 APR 29, 1993	> DLT >	> DLT >

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

> ADD >	+	BAXTER	EQ 10MG BASE/ML	N63221 001
> ADD >				APR 29, 1993

FORTAZ IN PLASTIC CONTAINER

> DLT >	**AP**	+ GLAXO WELLCOME	**EQ 10MG BASE/ML**	**N50634 001**
> DLT >				APR 28, 1989
> ADD >		@	EQ 10MG BASE/ML	N50634 001
> ADD >				APR 28, 1989

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN

> DLT >		ROCHE	EQ 500MG BASE/VIAL	N62654 001
> DLT >				APR 30, 1987
> ADD >		@	EQ 500MG BASE/VIAL	N62654 001
> ADD >				APR 30, 1987

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

AB		YOSHITOMI	**EQ 250MG BASE**	**N62872 001**
				JUN 20, 1988
AB			**EQ 500MG BASE**	**N62871 001**
				JUL 05, 1988
		@	EQ 250MG BASE	N62872 001
				JUN 20, 1988
		@	EQ 500MG BASE	N62871 001
				JUL 05, 1988

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

	+	BAXTER	EQ 20MG BASE/ML	N62422 003
				JAN 31, 1984
			EQ 20MG BASE/ML	N62422 005
				JUL 16, 1991
			EQ 20MG BASE/ML	N62730 001
				MAR 05, 1987
	+		EQ 40MG BASE/ML	N62422 004
				JAN 31, 1984

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION
CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

		BAXTER	EQ 40MG BASE/ML	N62422 006
				JUL 16, 1991
			EQ 40MG BASE/ML	N62730 002
				MAR 05, 1987
		@	EQ 20MG BASE/ML	N62422 003
				JAN 31, 1984
		@	EQ 20MG BASE/ML	N62422 005
				JUL 16, 1991
		@	EQ 20MG BASE/ML	N62730 001
				MAR 05, 1987
		@	EQ 40MG BASE/ML	N62422 004
				JAN 31, 1984
		@	EQ 40MG BASE/ML	N62422 006
				JUL 16, 1991
		@	EQ 40MG BASE/ML	N62730 002
				MAR 05, 1987

CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER

	+	BAXTER	EQ 20MG BASE/ML	N62422 001
				JAN 31, 1984
	+		EQ 40MG BASE/ML	N62422 002
				JAN 31, 1984
		@	EQ 20MG BASE/ML	N62422 001
				JAN 31, 1984
		@	EQ 40MG BASE/ML	N62422 002
				JAN 31, 1984

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
CHLORDIAZEPOXIDE HCL

AB	HALSEY	**5MG**	**N85340 001**
AB		**10MG**	**N85339 001**
AB		**25MG**	**N84685 001**
	@	5MG	N85340 001
	@	10MG	N85339 001
	@	25MG	N84685 001

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
CHLORHEXIDINE GLUCONATE

AT	HI TECH PHARMA	**0.12%**	**N74356 001**
			MAY 07, 1996

CHLORPROPAMIDE

TABLET; ORAL
CHLORPROPAMIDE

AB	BARR	**100MG**	**N88812 001 OCT 19, 1984**
AB		**100MG**	**N89446 001 NOV 17, 1986**
AB		**250MG**	**N88813 001 OCT 19, 1984**
AB		**250MG**	**N89447 001 NOV 17, 1986**
@		100MG	N88812 001 OCT 19, 1984
@		100MG	N89446 001 NOV 17, 1986
@		250MG	N88813 001 OCT 19, 1984
@		250MG	N89447 001 NOV 17, 1986
AB	HALSEY	**100MG**	**N89321 001 JAN 16, 1986**
AB		**250MG**	**N88662 001 JAN 09, 1986**
@		100MG	N89321 001 JAN 16, 1986
@		250MG	N88662 001 JAN 09, 1986
AB	SUPERPHARM	**250MG**	**N88695 001 SEP 17, 1984**
@		250MG	N88695 001 SEP 17, 1984

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE

AB	SUPERPHARM	**50MG**	**N87247 001 FEB 09, 1983**
@		50MG	N87247 001 FEB 09, 1983

CHOLESTYRAMINE

POWDER; ORAL
PREVALITE

AB	UPSHER SMITH	**EQ 4GM RESIN/PACKET**	**N73263 001 FEB 22, 1996**

CHOLESTYRAMINE

POWDER; ORAL
QUESTRAN

AB	+ BRISTOL MYERS	**EQ 4GM RESIN/PACKET**	**N16640 001**
AB		**EQ 4GM RESIN/SCOOPFUL**	**N16640 003**

QUESTRAN LIGHT

AB	+ BRISTOL MYERS	**EQ 4GM RESIN/PACKET**	**N19669 001 DEC 05, 1988**
AB		**EQ 4GM RESIN/PACKET**	**N19669 001 DEC 05, 1988**
AB		**EQ 4GM RESIN/SCOOPFUL**	**N19669 003 DEC 05, 1988**

CHROMIC CHLORIDE

INJECTABLE; INJECTION
CHROMIC CHLORIDE

AP	FUJISAWA	**EQ 0.004MG CHROMIUM/ML**	**N19271 001 MAY 05, 1987**
@		EQ 0.004MG CHROMIUM/ML	N19271 001 MAY 05, 1987

CHROMIC CHLORIDE IN PLASTIC CONTAINER

AP	+ ABBOTT	**EQ 0.004MG CHROMIUM/ML**	**N18961 001 JUN 26, 1986**
+		EQ 0.004MG CHROMIUM/ML	N18961 001 JUN 26, 1986

> ADD >

> ADD >

> ADD >

> ADD >

CIDOFOVIR

INJECTABLE; INJECTION
VISTIDE

+	GILEAD	EQ 75MG BASE/ML	N20638 001 JUN 26, 1996

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	DANBURY PHARMA	**800MG**	**N74316 001 FEB 28, 1996**
AB	INVAMED	**200MG**	**N74506 001 JAN 24, 1996**
AB		**300MG**	**N74506 002 JAN 24, 1996**

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	INVAMED	**400MG**	**N74506 003**	
			JAN 24, 1996	
AB		**800MG**	**N74506 004**	
			JAN 24, 1996	

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HCL

AP	MOVA	**EQ 300MG BASE/2ML**	**N74428 001**
			APR 25, 1996

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL
CIPRO

	BAYER	EQ 100MG BASE	N19537 001
			APR 08, 1996

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL
CLOBETASOL PROPIONATE

AB	FOUGERA	**0.05%**	**N74407 001**
			FEB 23, 1996

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
ANAFRANIL

AB	CIBA GEIGY	**25MG**	**N19906 001**	
			DEC 29, 1989	
AB	+	**50MG**	**N19906 002**	> DLT >
			DEC 29, 1989	> DLT >
AB		**75MG**	**N19906 003**	
			DEC 29, 1989	> ADD >

CLOMIPRAMINE HCL

AB	GENEVA PHARMS	**25MG**	**N74364 001**	
			MAR 29, 1996	
AB		**50MG**	**N74364 002**	
			MAR 29, 1996	

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
CLOMIPRAMINE HCL

AB	GENEVA PHARMS	**75MG**	**N74364 003**
			MAR 29, 1996

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PHERAZINE VC W/ CODEINE

AA	HALSEY	**10MG/5ML;5MG/5ML; 6.25MG/5ML**	**N88870 001**
			MAR 02, 1987
	@	10MG/5ML;5MG/5ML; 6.25MG/5ML	N88870 001
			MAR 02, 1987

CORTICORELIN OVINE TRIFLUTATE

INJECTABLE; INJECTION
ACTHREL

	+ FERRING LABS	EQ 0.1MG BASE/VIAL	N20162 001
			MAY 23, 1996

CROMOLYN SODIUM

CONCENTRATE; ORAL
GASTROCROM

	+ FISONS	100MG/5ML	N20479 001
			FEB 29, 1996

CYANOCOBALAMIN

INJECTABLE; INJECTION
BETALIN 12

AP	LILLY	**0.1MG/ML**	**N80855 001**
AP		**1MG/ML**	**N80855 002**
	@	0.1MG/ML	N80855 001
	@	1MG/ML	N80855 002

CYCLOTHIAZIDE

TABLET; ORAL
ANHYDRON
+ LILLY 2MG N13157 002
@ 2MG N13157 002

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL
CYPROHEPTADINE HCL
AA HALSEY 2MG/5ML N89199 001 JUL 03, 1986
@ 2MG/5ML N89199 001 JUL 03, 1986

DALTEPARIN SODIUM

INJECTABLE; INJECTION
FRAGMIN
+ PHARMACIA AND UPJOHN 5,000 IU/0.2ML N20287 003 MAR 18, 1996

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION
DAUNOXOME
+ NEXSTAR EQ 2MG BASE/ML N50704 002 APR 08, 1996

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HCL
AB EON LABS 10MG N74430 001 FEB 09, 1996
AB 150MG N74430 002 FEB 09, 1996

DESOXIMETASONE

OINTMENT; TOPICAL
DESOXIMETASONE
> ADD > AB TARO 0.25% N74286 001 JUN 07, 1996

DESOXIMETASONE

OINTMENT; TOPICAL
TOPICORT
> ADD > AB + HOECHST MARION RSSL 0.25% N18763 001 SEP 30, 1983

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
DEXACIDIN
AT CIBA 0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N62566 001 FEB 22, 1985
AT IOLAB 0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N62566 001 FEB 22, 1985

SUSPENSION/DROPS; OPHTHALMIC
DEXACIDIN
AT CIBA 0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML N62544 001 OCT 29, 1984
AT IOLAB 0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML N62544 001 OCT 29, 1984

DEXFENFLURAMINE HYDROCHLORIDE

CAPSULE; ORAL
REDUX
+ INTERNEURON 15MG N20344 001 APR 29, 1996

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXTROAMPHETAMINE SULFATE
AA HALSEY 10MG N83930 001
@ 10MG N83930 001
AA MM MAST 5MG N86521 001
@ 5MG N86521 001
AA + REXAR 10MG N84051 002
+ 10MG N84051 002

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

	PHERAZINE DM				
AA	HALSEY	**15MG/5ML;6.25MG/5ML**	**N88913 001**	> ADD >	
			MAR 02, 1987	> ADD >	
	@	15MG/5ML;6.25MG/5ML	N88913 001		
			MAR 02, 1987		

DIATRIZOATE SODIUM

SOLUTION; URETERAL

	HYPAQUE SODIUM 20%				
> DLT > **AT**	NYCOMED	**20%**	**N09561 002**		
> ADD >		20%	N09561 002		

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

	DICLOFENAC SODIUM				
AB	PUREPAC PHARM	**50MG**	**N74514 001**		
			MAR 26, 1996		
AB		**75MG**	**N74514 002**		
			MAR 26, 1996		

TABLET, EXTENDED RELEASE; ORAL

	VOLTAREN-XR				
	+ GEIGY	100MG	N20254 001		
			MAR 08, 1996		

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

	DICYCLOMINE HCL				
AB	LANNETT	**10MG**	**N84285 001**		

INJECTABLE; INJECTION

> ADD >	**BENTYL PRESERVATIVE FREE**				
> ADD > **AP**	HOECHST MARION RSSL	**10MG/ML**	**N08370 002**		
> ADD >			OCT 15, 1984		

DIFLUNISAL

TABLET; ORAL

	DIFLUNISAL				
AB	GENEVA PHARMS	**500MG**	**N74604 001**		
			JUN 10, 1996		
AB	PUREPAC PHARM	**250MG**	**N74285 001**		
			MAY 07, 1996		
AB		**500MG**	**N74285 002**		
			MAY 07, 1996		

DIGOXIN

INJECTABLE; INJECTION

	DIGOXIN				
AP	SANOFI WINTHROP	**0.25MG/ML**	**N40093 001**		
			MAY 16, 1996		
	DIGOXIN PEDIATRIC				
AP	SANOFI WINTHROP	**0.1MG/ML**	**N40092 001**		
			APR 25, 1996		
	LANOXIN				
	+ GLAXO WELLCOME	0.1MG/ML	N09330 004		
	LANOXIN PEDIATRIC				
AP	+ GLAXO WELLCOME	**0.1MG/ML**	**N09330 004**		

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

	CARDIZEM				
AP	+ HOECHST MARION RSSL	**5MG/ML**	**N20027 001**		
			OCT 24, 1991		
	DILTIAZEM HCL				
AP	BEDFORD	**5MG/ML**	**N74617 001**		
			FEB 28, 1996		

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

	DIPHENHYDRAMINE HCL				
AA	HALSEY	**50MG**	**N87914 001**		
			JUN 04, 1984		
	@	50MG	N87914 001		
			JUN 04, 1984		

ELIXIR; ORAL

	BELIX				
AA	HALSEY	**12.5MG/5ML**	**N86586 001**		
			OCT 03, 1983		

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL
BELIX
@ HALSEY — 12.5MG/5ML — N86586 001 OCT 03, 1983

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL
DISOPYRAMIDE PHOSPHATE
B* KV PHARM — EQ 100MG BASE — N71929 001 AUG 19, 1988
@ — EQ 100MG BASE — N71929 001 AUG 19, 1988

NORPACE CR
AB SEARLE — EQ 100MG BASE — N18655 001 JUL 20, 1982
EQ 100MG BASE — N18655 001 JUL 20, 1982

DOCETAXEL

INJECTABLE; INJECTION
TAXOTERE
+ RHONE POULENC — EQ 40MG BASE/ML — N20449 001 MAY 14, 1996

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HCL
AP SANOFI WINTHROP — 40MG/ML — N74403 001 MAY 23, 1996

DOXYCYCLINE HYCLATE

TABLET; ORAL
DOXYCYCLINE HYCLATE
AB SUPERPHARM — EQ 100MG BASE — N62494 001 FEB 20, 1985
@ — EQ 100MG BASE — N62494 001 FEB 20, 1985

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
EDROPHONIUM CHLORIDE
AP STERIS — 10MG/ML — N40044 001 MAR 20, 1996

EDROPHONIUM CHLORIDE PRESERVATIVE FREE
AP STERIS — 10MG/ML — N40043 001 MAR 20, 1996

TENSILON PRESERVATIVE FREE
AP + ROCHE — 10MG/ML — N07959 002

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL W/ EPINEPHRINE
AP ABBOTT — 0.01MG/ML;1% — N83154 001
@ — 0.01MG/ML;1% — N83154 001

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL
ILOSONE
> DLT > AB DISTA — EQ 125MG BASE/5ML — N61894 001
> DLT > AB + — EQ 250MG BASE/5ML — N61894 002
> ADD > @ — EQ 125MG BASE/5ML — N61894 001
> ADD > @ — EQ 250MG BASE/5ML — N61894 002
> ADD > AB LILLY — EQ 125MG BASE/5ML — N50010 001
> ADD > AB + — EQ 250MG BASE/5ML — N50010 002

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION
ERYTHROCIN
AP ABBOTT — EQ 500MG BASE/VIAL — N62586 001 JAN 04, 1988
AP — EQ 1GM BASE/VIAL — N62586 002 JAN 04, 1988
@ — EQ 500MG BASE/VIAL — N62586 001 JAN 04, 1988
@ — EQ 1GM BASE/VIAL — N62586 002 JAN 04, 1988

ESTRADIOL

INSERT, EXTENDED RELEASE; VAGINAL
ESTRING
+ PHARMACIA AND UPJOHN 0.0075MG/24HR N20472 001 APR 26, 1996

TABLET; ORAL
ESTRACE
AB BRISTOL MYERS SQUIBB 0.5MG N81295 001 JUN 30, 1993
AB 1MG N84499 001
AB + 2MG N84500 001
ESTRADIOL
AB WATSON LABS 0.5MG N40114 003 MAR 14, 1996
AB 1MG N40114 001 MAR 14, 1996
AB 2MG N40114 002 MAR 14, 1996

ESTRONE

INJECTABLE; INJECTION
ESTROGENIC SUBSTANCE
BP + WYETH AYERST 2MG/ML N83488 001
@ 2MG/ML N83488 001
NATURAL ESTROGENIC SUBSTANCE-ESTRONE
BP STERIS 2MG/ML N85237 001 NOV 23, 1982
+ 2MG/ML N85237 001 NOV 23, 1982

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)
> DLT > > DLT > AB WATSON LABS 0.035MG,0.035MG;0.5MG,1MG N71041 001 SEP 24, 1991
> DLT > > ADD > AB + 0.035MG,0.035MG;0.5MG,1MG N71041 001 SEP 24, 1991
> ADD > > DLT > ORTHO-NOVUM 7/14-21
> DLT > > DLT > AB + JOHNSON RW 0.035MG,0.035MG;0.5MG,1MG N19004 001 APR 04, 1984
> DLT > > ADD > @ 0.035MG,0.035MG;0.5MG,1MG N19004 001 APR 04, 1984
> ADD > > ADD >

ETODOLAC

TABLET; ORAL
LODINE
> DLT > > DLT > + WYETH AYERST 400MG N18922 004 JUL 29, 1993
> DLT > > ADD > 400MG N18922 004 JUL 29, 1993
> ADD > > ADD > + 500MG N18922 005 JUN 28, 1996
> ADD > > ADD >

ETOPOSIDE

INJECTABLE; INJECTION
ETOPOSIDE
AP LEDERLE LABS 20MG/ML N74513 001 MAR 14, 1996
AP PHARMACHEMIE (NL) 20MG/ML N74227 001 FEB 22, 1996

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION
ETOPOPHOS
+ BRISTOL MYERS SQUIBB EQ 100MG BASE/VIAL N20457 001 MAY 17, 1996

EVANS BLUE

INJECTABLE; INJECTION
EVANS BLUE
@ PARKE DAVIS 0.5% N08041 001

FAMCICLOVIR

TABLET; ORAL
FAMVIR
SMITHKLINE BEECHAM 250MG N20363 001 APR 26, 1996

FAMOTIDINE

INJECTABLE; INJECTION

>DLT>		PEPCID IV PRESERVATIVE FREE			
>DLT>	+	MERCK	10MG/ML	N19510 004	
>DLT>				NOV 04, 1986	
>ADD>		PEPCID PRESERVATIVE FREE			
>ADD>	+	MERCK	10MG/ML	N19510 004	
>ADD>				NOV 04, 1986	

FLECAINIDE ACETATE

TABLET; ORAL

	TAMBOCOR			
>ADD>	@ 3M	200MG	N18830 002	
>ADD>			OCT 31, 1985	

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

		FLUOCINOLONE ACETONIDE			
>DLT>	AT	+ HAMILTON PHARMA CA	0.01%	N12787 004	
>DLT>	AT	+	0.025%	N12787 002	
>DLT>	AT	+	0.025%	N12787 005	
>DLT>		+	0.2%	N16161 002	
>ADD>		SYNALAR			
>ADD>	AT	+ HAMILTON PHARMA CA	0.01%	N12787 004	
>ADD>	AT	+	0.025%	N12787 002	
>ADD>	AT	+	0.025%	N12787 005	
>ADD>		SYNALAR-HP			
>ADD>		+ HAMILTON PHARMA CA	0.2%	N16161 002	

OINTMENT; TOPICAL

		FLUOCINOLONE ACETONIDE			
>DLT>	AT	+ HAMILTON PHARMA CA	0.025%	N13960 001	
>ADD>		SYNALAR			
>ADD>	AT	+ HAMILTON PHARMA CA	0.025%	N13960 001	

SOLUTION; TOPICAL

		FLUOCINOLONE ACETONIDE			
>DLT>	AT	+ HAMILTON PHARMA CA	0.01%	N15296 001	
>ADD>		SYNALAR			
>ADD>	AT	+ HAMILTON PHARMA CA	0.01%	N15296 001	

FLUOCINONIDE

CREAM; TOPICAL

		FLUOCINONIDE			
>DLT>	AB	+ HAMILTON PHARMA CA	0.05%	N16908 002	
		FLUOCINONIDE EMOLLIENT BASE			
>DLT>	AB	HAMILTON PHARMA CA	0.05%	N16908 003	
>ADD>		LIDEX			
>ADD>	AB	+ HAMILTON PHARMA CA	0.05%	N16908 002	
>ADD>		LIDEX-E			
>ADD>	AB	HAMILTON PHARMA CA	0.05%	N16908 003	

GEL; TOPICAL

		FLUOCINONIDE			
>DLT>	AB	+ HAMILTON PHARMA CA	0.05%	N17373 001	
>ADD>		LIDEX			
>ADD>	AB	+ HAMILTON PHARMA CA	0.05%	N17373 001	

OINTMENT; TOPICAL

		FLUOCINONIDE			
>DLT>	AB	+ HAMILTON PHARMA CA	0.05%	N16909 002	
>ADD>		LIDEX			
>ADD>	AB	+ HAMILTON PHARMA CA	0.05%	N16909 002	

SOLUTION; TOPICAL

		FLUOCINONIDE			
>DLT>	AT	+ HAMILTON PHARMA CA	0.05%	N18849 001	
>DLT>				APR 06, 1984	
>ADD>		LIDEX			
>ADD>	AT	+ HAMILTON PHARMA CA	0.05%	N18849 001	
>ADD>				APR 06, 1984	

FLUOROURACIL

INJECTABLE; INJECTION

		ADRUCIL			
	AP	+ PHARMACIA	50MG/ML	N40023 001	
				OCT 18, 1991	
	AP		50MG/ML	N40023 001	
				OCT 18, 1991	
		FLUOROURACIL			
	AP	ROCHE	50MG/ML	N12209 001	
	AP	+	50MG/ML	N12209 001	

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

	FLURAZEPAM HCL			
AB	SUPERPHARM	**15MG**	**N71659 001**	**AUG 04, 1988**
AB		**30MG**	**N71660 001**	**AUG 04, 1988**
@		15MG	N71659 001	AUG 04, 1988
@		30MG	N71660 001	AUG 04, 1988
AB	WARNER CHILCOTT	**30MG**	**N71768 001**	**DEC 04, 1987**
@		30MG	N71768 001	DEC 04, 1987

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

	FLOVENT			
	GLAXO WELLCOME	0.044MG/INH	N20548 001	MAR 27, 1996
		0.11MG/INH	N20548 002	MAR 27, 1996
+		0.22MG/INH	N20548 003	MAR 27, 1996

FOLIC ACID

TABLET; ORAL

	FOLIC ACID			
AA	HALSEY	**1MG**	**N83598 001**	
@		1MG	N83598 001	

FUROSEMIDE

TABLET; ORAL

	FUROSEMIDE			
AB	SUPERPHARM	**20MG**	**N18370 002**	**JUN 26, 1984**
AB		**40MG**	**N18370 001**	**FEB 10, 1983**
@		20MG	N18370 002	JUN 26, 1984

FUROSEMIDE

TABLET; ORAL

	FUROSEMIDE			
@	SUPERPHARM	40MG	N18370 001	FEB 10, 1983
AB	ZENITH GOLDLINE	**20MG**	**N18413 001**	**NOV 30, 1983**
AB		**40MG**	**N18413 002**	**NOV 30, 1983**
AB	ZENITH LABS	**20MG**	**N18413 001**	**NOV 30, 1983**
AB		**40MG**	**N18413 002**	**NOV 30, 1983**

GANCICLOVIR

IMPLANT; IMPLANTATION

	VITRASERT			
+	CHIRON VISION	4.5-6.4MG	N20569 001	MAR 04, 1996
+		4.5MG	N20569 001	MAR 04, 1996

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

	CYTOVENE		
+	SYNTEX	EQ 500MG BASE/VIAL	N19661 001 JUN 23, 1989
	CYTOVENE IV		
+	SYNTEX	EQ 500MG BASE/VIAL	N19661 001 JUN 23, 1989

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

	GEMZAR		
+	LILLY	EQ 200MG BASE/VIAL	N20509 001 MAY 15, 1996
+		EQ 1GM BASE/VIAL	N20509 002 MAY 15, 1996

> DLT >
> DLT >
> ADD >
> ADD >

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GENTAMICIN SULFATE

AP	ABBOTT	**EQ 60MG BASE/100ML**	**N62413 006**	**AUG 11, 1983**
AP		**EQ 70MG BASE/100ML**	**N62413 007**	**AUG 11, 1983**
AP		**EQ 80MG BASE/100ML**	**N62413 008**	**AUG 11, 1983**
AP		**EQ 90MG BASE/100ML**	**N62413 009**	**AUG 11, 1983**
AP		**EQ 100MG BASE/100ML**	**N62413 010**	**AUG 11, 1983**
AP		**EQ 1.2MG BASE/ML**	**N62413 001**	**AUG 11, 1983**
AP		**EQ 1.4MG BASE/ML**	**N62413 002**	**AUG 11, 1983**
AP		**EQ 1.6MG BASE/ML**	**N62413 003**	**AUG 11, 1983**
AP		**EQ 1.8MG BASE/ML**	**N62413 004**	**AUG 11, 1983**
AP		**EQ 2MG BASE/ML**	**N62413 005**	**AUG 11, 1983**
	@	EQ 60MG BASE/100ML	N62413 006	AUG 11, 1983
	@	EQ 70MG BASE/100ML	N62413 007	AUG 11, 1983
	@	EQ 80MG BASE/100ML	N62413 008	AUG 11, 1983
	@	EQ 90MG BASE/100ML	N62413 009	AUG 11, 1983
	@	EQ 100MG BASE/100ML	N62413 010	AUG 11, 1983
	@	EQ 1.2MG BASE/ML	N62413 001	AUG 11, 1983
	@	EQ 1.4MG BASE/ML	N62413 002	AUG 11, 1983
	@	EQ 1.6MG BASE/ML	N62413 003	AUG 11, 1983
	@	EQ 1.8MG BASE/ML	N62413 004	AUG 11, 1983
	@	EQ 2MG BASE/ML	N62413 005	AUG 11, 1983

OINTMENT; OPHTHALMIC
GENTACIDIN

AT	CIBA	**EQ 0.3% BASE**	**N62501 001**	**JUL 26, 1984**

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC
GENTACIDIN

AT	IOLAB	**EQ 0.3% BASE**	**N62501 001**	**JUL 26, 1984**

SOLUTION/DROPS; OPHTHALMIC
GENTACIDIN

AT	CIBA	**EQ 0.3% BASE**	**N62480 001**	**MAR 30, 1984**
AT	IOLAB	**EQ 0.3% BASE**	**N62480 001**	**MAR 30, 1984**

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE

AB	NOVOPHARM	**5MG**	**N74387 001**	**MAR 04, 1996**
AB		**10MG**	**N74387 002**	**MAR 04, 1996**

GLUTETHIMIDE

TABLET; ORAL
GLUTETHIMIDE

	HALSEY	250MG	N89458 001	OCT 10, 1986
	@	250MG	N89458 001	OCT 10, 1986

GLYBURIDE

TABLET; ORAL
GLYNASE

AB	+ PHARMACIA AND UPJOHN	**3MG**	**N20051 002**	**MAR 04, 1992**
	@	6MG	N20051 004	SEP 24, 1993
AB	UPJOHN	**3MG**	**N20051 002**	**MAR 04, 1992**
	+	6MG	N20051 004	SEP 24, 1993

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

> DLT >	AP	ABBOTT	0.2MG/ML	N89393 001	
> DLT >				JUN 15, 1988	
> ADD >		@	0.2MG/ML	N89393 001	
> ADD >				JUN 15, 1988	

GOSERELIN ACETATE

IMPLANT; IMPLANTATION

ZOLADEX

	+	ZENECA	EQ 10.8MG BASE	N20578 001
				JAN 11, 1996

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

AT	BAUSCH AND LOMB	0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML	N64047 001
			JAN 31, 1996

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALDOL DECANOATE 100

	+	JOHNSON RW	EQ 100MG BASE/ML
			OCT 31, 1989

HALOPROGIN

CREAM; TOPICAL

HALOTEX

	+	WESTWOOD SQUIBB	1%	N16942 001
		@	1%	N16942 001

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

> ADD >	AP	MARSAM	1,000 UNITS	N40007 001
> ADD >				JUN 07, 1996

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

> DLT >	AP	ORGANON	1,000 UNITS/ML	N00552 008
> DLT >	AP		5,000 UNITS/ML	N00552 009
> DLT >	AP		10,000 UNITS/ML	N00552 010
> ADD >		@	1,000 UNITS/ML	N00552 008
> ADD >		@	5,000 UNITS/ML	N00552 009
> ADD >		@	10,000 UNITS/ML	N00552 010

HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

> DLT >	AP	MCGAW	5,000 UNITS/100ML	N19134 001
> DLT >				MAR 29, 1985
> ADD >		@	5,000 UNITS/100ML	N19134 001
> ADD >				MAR 29, 1985

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HCL

AA		HALSEY	10MG	N89218 001
				JAN 22, 1986
		@	10MG	N89218 001
				JAN 22, 1986

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDRO-D

AB		HALSEY	25MG	N86504 001
AB			50MG	N83891 002
		@	25MG	N86504 001
		@	50MG	N83891 002

HYDROCHLOROTHIAZIDE

AB		BARR	50MG	N84771 001
		@	50MG	N84771 001
AB		SUPERPHARM	25MG	N88827 001
				DEC 28, 1984
AB			50MG	N88828 001
				DEC 28, 1984
AB			100MG	N88829 001
				DEC 28, 1984
		@	25MG	N88827 001
				DEC 28, 1984
		@	50MG	N88828 001
				DEC 28, 1984

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE

@	SUPERPHARM	100MG	N88829 001 DEC 28, 1984	> ADD >	

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL
METHYLDOPA AND HYDROCHLOROTHIAZIDE

AB	NOVOPHARM	**15MG;250MG**	**N71819 001** APR 08, 1988	> ADD >	
AB		**25MG;250MG**	**N71820 001** APR 08, 1988	> ADD >	
AB		**30MG;500MG**	**N71821 001** APR 08, 1988	> ADD >	
AB		**50MG;500MG**	**N71822 001** APR 08, 1988	> ADD >	
@		15MG;250MG	N71819 001 APR 08, 1988		
@		25MG;250MG	N71820 001 APR 08, 1988		
@		30MG;500MG	N71821 001 APR 08, 1988		
@		50MG;500MG	N71822 001 APR 08, 1988		
AB	PARKE DAVIS	**15MG;250MG**	**N71897 001** NOV 23, 1987		
AB		**25MG;250MG**	**N71898 001** NOV 23, 1987		
AB		**30MG;500MG**	**N71899 001** NOV 23, 1987		
AB		**50MG;500MG**	**N71900 001** NOV 23, 1987		
@		15MG;250MG	N71897 001 NOV 23, 1987		
@		25MG;250MG	N71898 001 NOV 23, 1987		
@		30MG;500MG	N71899 001 NOV 23, 1987		
@		50MG;500MG	N71900 001 NOV 23, 1987		

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL
DYAZIDE

AB	+ SMITHKLINE BEECHAM	**25MG;37.5MG**	**N16042 003** MAR 03, 1994		

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	**25MG;37.5MG**	**N74701 001** JUN 07, 1996		

TABLET; ORAL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	SIDMAK LABS NJ	**25MG;37.5MG**	**N74026 001** APR 26, 1996		
AB		**50MG;75MG**	**N73467 001** JAN 31, 1996		

HYDROCORTISONE

CREAM; TOPICAL
HYDROCORTISONE

AT	AMBIX	**1%**	**N86080 001**		
AT		**2.5%**	**N86271 001**		
@		1%	N86080 001		
@		2.5%	N86271 001		

OINTMENT; TOPICAL
HYDROCORTISONE

AT	AMBIX	**1%**	**N86079 001**		
AT		**2.5%**	**N86272 001**		
@		1%	N86079 001		
@		2.5%	N86272 001		

PENECORT

AT	ALLERGAN HERBERT	**2.5%**	**N88217 001** JUN 06, 1984		
@		2.5%	N88217 001 JUN 06, 1984		

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-HYDROCORT

AP	ABBOTT	**EQ 100MG BASE/VIAL**	**N85928 001**		
@		EQ 100MG BASE/VIAL	N85928 001		

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL
HYDROXYCHLOROQUINE SULFATE

AB	INVAMED	200MG	N40150 001 JAN 27, 1996

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL
HYDROXYZINE HCL

AB	HALSEY	10MG	N89366 001 MAY 02, 1988
@		10MG	N89366 001 MAY 02, 1988
AB	SUPERPHARM	10MG	N88794 001 DEC 05, 1984
AB		25MG	N88795 001 DEC 05, 1984
AB		50MG	N88796 001 DEC 05, 1984
@		10MG	N88794 001 DEC 05, 1984
@		25MG	N88795 001 DEC 05, 1984
@		50MG	N88796 001 DEC 05, 1984

IBUPROFEN

SUSPENSION; ORAL
CHILDREN'S MOTRIN

BX	+ MCNEIL CONS PRODS	100MG/5ML	N19842 001 SEP 19, 1989

MOTRIN

BX	+ MCNEIL CONS PRODS	100MG/5ML	N19842 001 SEP 19, 1989

TABLET; ORAL
IBUPROFEN

AB	HALSEY	300MG	N71028 001 MAR 23, 1987
AB		400MG	N71029 001 MAR 23, 1987
AB		600MG	N71030 001 MAR 23, 1987

IBUPROFEN

TABLET; ORAL
IBUPROFEN

AB	HALSEY	800MG	N72137 001 FEB 05, 1988
@		300MG	N71028 001 MAR 23, 1987
@		400MG	N71029 001 MAR 23, 1987
@		600MG	N71030 001 MAR 23, 1987
@		800MG	N72137 001 FEB 05, 1988

INDAPAMIDE

TABLET; ORAL
INDAPAMIDE

AB	INVAMED	1.25MG	N74594 001 MAY 23, 1996
AB		2.5MG	N74594 002 MAY 23, 1996
AB	MYLAN	2.5MG	N74461 001 MAR 27, 1996
AB	PUREPAC PHARM	1.25MG	N74722 001 JUN 17, 1996
AB		2.5MG	N74722 002 JUN 17, 1996
AB	ZENITH GOLDLINE	1.25MG	N74299 002 APR 29, 1996
AB		2.5MG	N74299 001 JUL 27, 1995
AB	ZENITH LABS	2.5MG	N74299 001 JUL 27, 1995

LOZOL

AB	RHONE POULENC RORER	1.25MG	N18538 002 APR 29, 1993

INDINAVIR SULFATE

CAPSULE; ORAL
CRIXIVAN

	MERCK	EQ 200MG BASE	N20685 003 MAR 13, 1996
+		EQ 400MG BASE	N20685 001 MAR 13, 1996

INDOMETHACIN

CAPSULE; ORAL
INDOMETHACIN

AB	HALSEY	25MG	N70782 001 JUN 03, 1987	
AB		50MG	N70635 001 JUN 03, 1987	
@		25MG	N70782 001 JUN 03, 1987	
@		50MG	N70635 001 JUN 03, 1987	
AB	PARKE DAVIS	25MG	N18806 001 NOV 23, 1984	
AB		50MG	N18806 002 NOV 23, 1984	
@		25MG	N18806 001 NOV 23, 1984	
@		50MG	N18806 002 NOV 23, 1984	

> ADD > INSULIN LISPRO

> ADD > INJECTABLE; INJECTION
> ADD > HUMALOG
> ADD > + LILLY 100 UNITS/ML N20563 001 JUN 14, 1996
> ADD >

IODIXANOL

INJECTABLE; INJECTION
VISIPAQUE 270
+ NYCOMED 55% N20351 001 MAR 22, 1996

VISIPAQUE 320
+ NYCOMED 65.2% N20351 002 MAR 22, 1996

IOPAMIDOL

INJECTABLE; INJECTION
ISOVUE-200
@ BRACCO 41% N20327 001 OCT 12, 1994

ISOVUE-250
BRACCO 51% N20327 002 OCT 12, 1994

IOPAMIDOL

INJECTABLE; INJECTION
ISOVUE-300
BRACCO 61% N20327 003 OCT 12, 1994

ISOVUE-370
BRACCO 76% N20327 004 OCT 12, 1994

INJECTABLE; INTRAVASCULAR
ISOVUE-200
@ BRACCO 41% N20327 001 OCT 12, 1994

ISOVUE-250
BRACCO 51% N20327 002 OCT 12, 1994

ISOVUE-300
BRACCO 61% N20327 003 OCT 12, 1994

ISOVUE-370
BRACCO 76% N20327 004 OCT 12, 1994

> ADD > IRINOTECAN HYDROCHLORIDE

> ADD > INJECTABLE; INJECTION
> ADD > CAMPTOSAR
> ADD > + PHARMACIA AND UPJOHN 20MG/ML N20571 001 JUN 14, 1996
> ADD >

IRON DEXTRAN

INJECTABLE; INJECTION
DEXFERRUM
BP LUITPOLD EQ 50MG IRON/ML N40024 001 FEB 23, 1996

ISONIAZID

TABLET; ORAL
ISONIAZID

> DLT > AA	DANBURY PHARMA	50MG		N80522 001
> DLT > AA		100MG		N80523 001
> ADD >	@	50MG		N80522 001
> ADD >	@	100MG		N80523 001

ISONIAZID

TABLET; ORAL

		ISONIAZID			
> DLT >	AA	DURAMED	100MG	N88231 001	
> DLT				MAR 17, 1983	
> ADD >		@	100MG	N88231 001	
> ADD >				MAR 17, 1983	
> ADD >		@ GLOBAL PHARM	100MG	N80153 001	
> DLT >	AA	GLOBAL PHARMS	100MG	N80153 001	
> DLT >	AA	PHOENIX LABS NY	50MG	N80368 001	
> DLT >	AA		100MG	N80368 002	
> ADD >		@	50MG	N80368 001	
> ADD >		@	100MG	N80368 002	
> DLT >	AA	ZENITH LABS	100MG	N80270 001	
> DLT >	AA		300MG	N83610 001	
> ADD >		@	100MG	N80270 001	
> ADD >		@	300MG	N83610 001	

ISOSORBIDE DINITRATE

TABLET; ORAL

		SORBITRATE			
> ADD >	BX	ZENECA	5MG	N16192 001	
> ADD >				APR 01, 1996	
> ADD >	BX		10MG	N16192 002	
> ADD >				APR 01, 1996	

TABLET; SUBLINGUAL

> ADD >		SORBITRATE			
> ADD >	BX	ZENECA	2.5MG	N16191 002	
> ADD >				APR 01, 1996	
> ADD >	BX		5MG	N16191 001	
> ADD >				APR 01, 1996	

TABLET, CHEWABLE; ORAL

> ADD >		SORBITRATE			
> ADD >		ZENECA	5MG	N16776 002	
> ADD >				APR 01, 1996	
> ADD >		+	10MG	N16776 003	
> ADD >				APR 01, 1996	

ISOSORBIDE MONONITRATE

TABLET; ORAL

		MONOKET			
		+ SCHWARZ	10MG	N20215 002	
				JUN 30, 1993	

ISOSORBIDE MONONITRATE

TABLET; ORAL

		MONOKET			
		SCHWARZ	10MG	N20215 002	
				JUN 30, 1993	

TABLET, EXTENDED RELEASE; ORAL

		IMDUR			
		@ SCHERING	30MG	N20225 001	
				AUG 12, 1993	
		+	30MG	N20225 001	
				AUG 12, 1993	

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

		KETALAR			
AP	+	PARKE DAVIS	EQ 50MG BASE/ML	N16812 002	
AP	+		EQ 100MG BASE/ML	N16812 003	
		KETAMINE HCL			
AP		BEDFORD	EQ 50MG BASE/ML	N74524 001	
				MAR 22, 1996	
AP			EQ 100MG BASE/ML	N74524 002	
				MAR 22, 1996	
AP		SANOFI WINTHROP	EQ 50MG BASE/ML	N74549 001	
				JUN 27, 1996	
AP			EQ 100MG BASE/ML	N74549 002	
				JUN 27, 1996	

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

> ADD >		XALATAN			
> ADD >	+	PHARMACIA AND UPJOHN	0.005%	N20597 001	
> ADD >				JUN 05, 1996	

LEUCOVORIN CALCIUM

POWDER FOR RECONSTITUTION; ORAL

> DLT >		LEUCOVORIN CALCIUM			
> DLT >		IMMUNEX	EQ 60MG BASE/VIAL	N08107 003	
> DLT >				JAN 30, 1987	
> ADD >		@	EQ 60MG BASE/VIAL	N08107 003	
> ADD >				JAN 30, 1987	

LIDOCAINE

FILM, EXTENDED RELEASE; BUCCAL
LIDOCAINE
+ NOVEN — 23MG/PATCH — N20575 001 MAY 21, 1996
+ — 46.1MG/PATCH — N20575 002 MAY 21, 1996

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL
AP ABBOTT — **20%** — **N89362 001 MAY 25, 1988**
@ — 20% — N89362 001 MAY 25, 1988

SOLUTION; ORAL
LIDOCAINE HCL
AT MORTON GROVE — **2%** — N87872 001 NOV 18, 1982

LIDOCAINE HCL VISCOUS
AT INTL MEDICATION — **2%** — **N86389 001 FEB 02, 1982**
@ — 2% — N86389 001 FEB 02, 1982

MYLOCAINE
AT MORTON GROVE — **2%** — **N87872 001 NOV 18, 1982**

SOLUTION; TOPICAL
ANESTACON
AT + ALCON — **2%** — **N80429 001**
AT + POLYMEDICA — **2%** — **N80429 001**
LIDOCAINE HCL
AT MORTON GROVE — **4%** — **N87881 001 NOV 18, 1982**

MYLOCAINE
AT MORTON GROVE — **4%** — **N87881 001 NOV 18, 1982**

LINDANE

CREAM; TOPICAL
KWELL
+ REED AND CARNRICK — 1% — N06309 001

LINDANE

CREAM; TOPICAL
KWELL
REED AND CARNRICK — 1% — N84218 001
@ — 1% — N06309 001
+ — 1% — N84218 001

LOTION; TOPICAL
KWELL
AT + REED AND CARNRICK — **1%** — **N06309 003**
AT — **1%** — **N84218 002**
AT + — **1%** — **N84218 002**
@ — 1% — N06309 003

SHAMPOO; TOPICAL
KWELL
AT + REED AND CARNRICK — **1%** — **N10718 001**
AT — **1%** — **N84219 001**
AT + — **1%** — **N84219 001**
@ — 1% — N10718 001

LITHIUM CITRATE

SYRUP; ORAL
CIBALITH-S
AA SOLVAY — **EQ 300MG CARBONATE/5ML** — **N17672 001**
LITHONATE
@ SOLVAY — EQ 300MG CARBONATE/5ML — N17672 001

LORACARBEF

CAPSULE; ORAL
LORABID
+ LILLY — 200MG — N50668 001 DEC 31, 1991
— 200MG — N50668 001 DEC 31, 1991
+ — 400MG — N50668 002 APR 05, 1996

LORAZEPAM

TABLET; ORAL
LORAZEPAM
AB HALSEY — **0.5MG** — **N71434 001 SEP 01, 1987**

LORAZEPAM

TABLET; ORAL

	LORAZEPAM			
AB	**HALSEY**	**1MG**	**N71435 001**	**SEP 01, 1987**
AB		**2MG**	**N71436 001**	**SEP 01, 1987**
	@	0.5MG	N71434 001	SEP 01, 1987
	@	1MG	N71435 001	SEP 01, 1987
	@	2MG	N71436 001	SEP 01, 1987
AB	**SUPERPHARM**	**0.5MG**	**N71245 001**	**FEB 09, 1987**
AB		**1MG**	**N71246 001**	**FEB 09, 1987**
AB		**2MG**	**N71247 001**	**FEB 09, 1987**
	@	0.5MG	N71245 001	FEB 09, 1987
	@	1MG	N71246 001	FEB 09, 1987
	@	2MG	N71247 001	FEB 09, 1987

MANGANESE CHLORIDE

INJECTABLE; INJECTION

	MANGANESE CHLORIDE IN PLASTIC CONTAINER			
	ABBOTT	**EQ 0.1MG MANGANESE/ML**	**N18962 001**	**JUN 26, 1986**
	@	EQ 0.1MG MANGANESE/ML	N18962 001	JUN 26, 1986

MANGANESE SULFATE

INJECTABLE; INJECTION

	MANGANESE SULFATE			
	FUJISAWA	**EQ 0.1MG MANGANESE/ML**	**N19228 001**	**MAY 05, 1987**
	@	EQ 0.1MG MANGANESE/ML	N19228 001	MAY 05, 1987

>ADD>

MECLOFENAMATE SODIUM

CAPSULE; ORAL

	MECLOFENAMATE SODIUM			
AB	**BARR**	**EQ 50MG BASE**	**N72848 001**	**MAR 20, 1989**
AB		**EQ 100MG BASE**	**N72809 001**	**MAR 20, 1989**
	@	EQ 50MG BASE	N72848 001	MAR 20, 1989
	@	EQ 100MG BASE	N72809 001	MAR 20, 1989

MEPROBAMATE

TABLET; ORAL

	MEPROBAMATE		
AA	**BARR**	**600MG**	**N84230 001**
	@	600MG	N84230 001
	NEURAMATE		
AA	**HALSEY**	**200MG**	**N14359 002**
AA		**400MG**	**N14359 001**
	@	200MG	N14359 002
	@	400MG	N14359 001

>ADD>

MEROPENEM

INJECTABLE; INJECTION

	MERREM I.V.			
	+ ZENECA	**500MG/VIAL**	**N50706 003**	**JUN 21, 1996**
	+	1GM/VIAL	N50706 001	JUN 21, 1996

>ADD>

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

	METHADOSE			
AA	**MALLINCKRODT**	**10MG/ML**	**N17116 002**
AA	**+**	**10MG/ML**	**N17116 002**

METHYLDOPA

TABLET; ORAL
METHYLDOPA

AB	HALSEY	500MG	N71753 001	MAR 28, 1988
@		500MG	N71753 001	MAR 28, 1988
AB	NOVOPHARM	125MG	N71105 001	DEC 05, 1986
AB		250MG	N71106 001	DEC 05, 1986
AB		500MG	N71067 001	DEC 05, 1986
@		125MG	N71105 001	DEC 05, 1986
@		250MG	N71106 001	DEC 05, 1986
@		500MG	N71067 001	DEC 05, 1986

METHYLTESTOSTERONE

TABLET; ORAL
ORETON METHYL

BP	SCHERING	25MG	N03158 002
@		25MG	N03158 002

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

> DLT >	AP	ABBOTT	EQ 10MG BASE/2ML	N70505 001	JUN 23, 1989
> DLT >					
> ADD >	AP		EQ 5MG BASE/ML	N70505 001	JUN 23, 1989
> ADD >					
> DLT >	AP		EQ 10MG BASE/2ML	N70506 001	JUN 22, 1989
> DLT >					
> ADD >	AP		EQ 5MG BASE/ML	N70506 001	JUN 22, 1989
> ADD >					
> DLT >	AP		EQ 10MG BASE/2ML	N73117 001	JAN 17, 1991
> DLT >					
> ADD >	AP		EQ 5MG BASE/ML	N73117 001	JAN 17, 1991
> ADD >					
> DLT >	AP		EQ 10MG BASE/2ML	N73118 001	JAN 17, 1991
> DLT >					
> ADD >	AP		EQ 5MG BASE/ML	N73118 001	JAN 17, 1991
> ADD >					
> DLT >	AP	BULL D	EQ 10MG BASE/2ML	N71990 001	JAN 18, 1989
> DLT >					
> DLT >	AP	CETUS BEN VENUE	EQ 10MG BASE/2ML	N72155 001	MAR 30, 1992
> DLT >					
> ADD >	AP		EQ 5MG BASE/ML	N72155 001	MAR 30, 1992
> ADD >					
> DLT >	AP		EQ 10MG BASE/2ML	N72244 001	MAR 30, 1992
> DLT >					
> ADD >	AP		EQ 5MG BASE/ML	N72244 001	MAR 30, 1992
> ADD >					
> DLT >	AP		EQ 10MG BASE/2ML	N72247 001	MAY 18, 1992
> DLT >					
> ADD >	AP		EQ 5MG BASE/ML	N72247 001	MAY 18, 1992
> ADD >					
> DLT >	AP	FAULDING	EQ 10MG BASE/2ML	N70847 001	NOV 07, 1988
> DLT >					
> ADD >	AP		EQ 5MG BASE/ML	N70847 001	NOV 07, 1988
> ADD >					
> DLT >	AP		EQ 10MG BASE/2ML	N71291 001	MAR 03, 1989
> DLT >					
> ADD >	AP		EQ 5MG BASE/ML	N71291 001	MAR 03, 1989
> ADD >					
> ADD >	AP		EQ 5MG BASE/ML	N71990 001	JAN 18, 1989
> ADD >					
> DLT >	AP	GENSIA	EQ 10MG BASE/2ML	N73135 001	NOV 27, 1991
> DLT >					
> ADD >	AP		EQ 5MG BASE/ML	N73135 001	NOV 27, 1991
> ADD >					
> DLT >	AP	SMITH AND NEPHEW	EQ 10MG BASE/2ML	N70623 001	MAR 02, 1987
> DLT >					
> ADD >	AP		EQ 5MG BASE/ML	N70623 001	MAR 02, 1987
> ADD >					
		REGLAN			
> DLT >	AP +	ROBINS AH	EQ 10MG BASE/2ML	N17862 001	
> ADD >	AP +		EQ 5MG BASE/ML	N17862 001	

TABLET; ORAL
METOCLOPRAMIDE HCL

AB	HALSEY	EQ 10MG BASE	N70906 001	OCT 28, 1986
@		EQ 10MG BASE	N70906 001	OCT 28, 1986

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL
METOCLOPRAMIDE HCL

AB	SCHERING	EQ 10MG BASE	N70598 001 FEB 02, 1987	
	@	EQ 10MG BASE	N70598 001 FEB 02, 1987	
AB	SUPERPHARM	EQ 10MG BASE	N70926 001 JUN 26, 1987	
	@	EQ 10MG BASE	N70926 001 JUN 26, 1987	

METRONIDAZOLE

TABLET; ORAL
METRONIDAZOLE

AB	HALSEY	250MG	N70021 001 APR 02, 1985	
AB		500MG	N70593 001 FEB 27, 1986	
	@	250MG	N70021 001 APR 02, 1985	
	@	500MG	N70593 001 FEB 27, 1986	
AB	ZENITH GOLDLINE	250MG	N18517 001	> ADD >
AB		500MG	N18517 002 MAY 05, 1982	> ADD >
AB	ZENITH LABS	250MG	N18517 001	> ADD >
AB		500MG	N18517 002 MAY 05, 1982	> ADD >

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL
MEXILETINE HCL

AB	GENEVA PHARMS	150MG	N74450 001 MAY 16, 1996	
AB		200MG	N74450 002 MAY 16, 1996	
AB		250MG	N74450 003 MAY 16, 1996	

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MONISTAT DUAL-PAK

+	JOHNSON RW	2%,200MG	N18888 002 OCT 17, 1988

MINOCYCLINE HYDROCHLORIDE

TABLET; ORAL
MINOCYCLINE HCL

	LEDERLE	EQ 100MG BASE	N50451 002 AUG 10, 1982	> DLT >
+	LEDERLE LABS	EQ 100MG BASE	N50451 002 AUG 10, 1982	> DLT >

MINOXIDIL

SOLUTION; TOPICAL
ROGAINE

+	UPJOHN	2%	N19501 001 AUG 17, 1988	> ADD >

MIRTAZAPINE

TABLET; ORAL
REMERON

	ORGANON	15MG	N20415 001 JUN 14, 1996	> ADD >
+		30MG	N20415 002 JUN 14, 1996	> ADD >

NADOLOL

TABLET; ORAL
NADOLOL

AB	ZENITH LABS	80MG	N74255 001 JAN 24, 1996	
AB		120MG	N74255 002 JAN 24, 1996	
AB		160MG	N74255 003 JAN 24, 1996	

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

>ADD>		NALBUPHINE HCL			
>ADD>		ABBOTT	1.5MG/ML	N20200 001	
>ADD>				MAR 12, 1993	
>DLT>		NALBUPHINE HYDROCHLORIDE			
>DLT>		ABBOTT	1.5MG/ML	N20200 001	
>DLT>				MAR 12, 1993	

NAPROXEN

TABLET; ORAL

		NAPROXEN		
	AB	BIOCRAFT	**250MG**	**N74216 001**
				APR 11, 1996
	AB		**375MG**	**N74216 002**
				APR 11, 1996
	AB		**500MG**	**N74216 003**
				APR 11, 1996
>ADD>	**AB**	SIDMAK LABS NJ	**250MG**	**N74182 001**
>ADD>				JUN 27, 1996
>ADD>	**AB**		**375MG**	**N74182 002**
>ADD>				JUN 27, 1996
>ADD>	**AB**		**500MG**	**N74182 003**
>ADD>				JUN 27, 1996

NAPROXEN SODIUM

TABLET; ORAL

		NAPROXEN SODIUM		
>ADD>	**AB**	SIDMAK LABS NJ	**EQ 250MG BASE**	**N74242 001**
>ADD>				JUN 20, 1996
>ADD>	**AB**		**EQ 500MG BASE**	**N74242 002**
>ADD>				JUN 20, 1996
	AB	WEST WARD PHARM	**EQ 500MG BASE**	**N74480 001**
				MAY 14, 1996

TABLET, EXTENDED RELEASE; ORAL

	NAPRELAN		
	+ ELAN PHARM	EQ 375MG BASE	N20353 001
			JAN 05, 1996
	+	EQ 500MG BASE	N20353 002
			JAN 05, 1996
	+	EQ 750MG BASE	N20353 003
			JAN 05, 1996

NEOMYCIN SULFATE

INJECTABLE; INJECTION

	MYCIFRADIN		
AP	+ UPJOHN	**EQ 350MG BASE/VIAL**	**N60477 001**
	NEOMYCIN SULFATE		
AP	PFIZER	**EQ 350MG BASE/VIAL**	**N61084 001**
AP	SQUIBB	**EQ 350MG BASE/VIAL**	**N60366 001**

POWDER; FOR RX COMPOUNDING

	NEO-RX		
AA	PHARMA TEK	**100%**	**N61579 001**
		100%	N61579 001
	NEOMYCIN SULFATE		
	@ ELKINS SINN	100%	N61698 001
AA	PADDOCK	**100%**	**N62385 001**
			JUN 01, 1982

>ADD> NEVIRAPINE

TABLET; ORAL

>ADD>	VIRAMUNE	
>ADD>	+ BOEHRINGER INGELHEIM	200MG
>ADD>		N20636 001
>ADD>		JUN 21, 1996

NICOTINE

SPRAY, METERED; NASAL

NICOTROL		
+ PHARMACIA	0.5MG/INH	N20385 001
		MAR 22, 1996

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICORETTE		
+ SMITHKLINE BEECHAM	EQ 2MG BASE	N18612 001
		JAN 13, 1984
NICORETTE DS		
+ SMITHKLINE BEECHAM	EQ 4MG BASE	N20066 001
		JUN 08, 1992

NITROFURAZONE

OINTMENT; TOPICAL

	NITROFURAZONE			
AT	**AMBIX**	**0.2%**		**N86077 001**
	@	0.2%		N86077 001

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

	NITRO-DUR			
BX	+ KEY PHARMS	0.1MG/HR		N20145 001 APR 04, 1995
BX	+	0.2MG/HR		N20145 002 APR 04, 1995
BX	+	0.4MG/HR		N20145 004 APR 04, 1995
BX	+	0.6MG/HR		N20145 005 APR 04, 1995
BX	+	0.8MG/HR		N20145 006 APR 04, 1995
	TRANSDERM-NITRO			
BX	CIBA	0.1MG/HR		N20144 001 FEB 27, 1996
BX	+	0.1MG/HR		N20144 001 FEB 27, 1996
BX		0.2MG/HR		N20144 002 FEB 27, 1996
BX	+	0.2MG/HR		N20144 002 FEB 27, 1996
BX		0.4MG/HR		N20144 003 FEB 27, 1996
BX	+	0.4MG/HR		N20144 003 FEB 27, 1996
BX		0.6MG/HR		N20144 004 FEB 27, 1996
BX	+	0.6MG/HR		N20144 004 FEB 27, 1996
BX		0.8MG/HR		N20144 005 FEB 27, 1996
BX	+	0.8MG/HR		N20144 005 FEB 27, 1996

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

	NORTRIPTYLINE HCL			
AB	BIOCRAFT	**EQ 10MG BASE**		**N73667 001** APR 11, 1996
AB		**EQ 25MG BASE**		**N73667 002** APR 11, 1996
AB		**EQ 50MG BASE**		**N73667 003** APR 11, 1996
AB		**EQ 75MG BASE**		**N73667 004** APR 11, 1996

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

	MYCOLOG-II			
AT	+ APOTHECON	**100,000 UNITS/GM;0.1%**		**N60576 002** MAY 01, 1985
	@	100,000 UNITS/GM;0.1%		N60576 002 MAY 01, 1985

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

	ZOFRAN PRESERVATIVE FREE			
	+ GLAXO WELLCOME	EQ 2MG BASE/ML		N20007 003 DEC 10, 1993

OXAZEPAM

TABLET; ORAL

	OXAZEPAM			
AB	PARKE DAVIS	**15MG**		**N71508 001** FEB 02, 1987
	@	15MG		N71508 001 FEB 02, 1987

OXTRIPHYLLINE

SOLUTION; ORAL

	CHOLEDYL			
	PARKE DAVIS	100MG/5ML		N09268 012 NOV 27, 1984

OXTRIPHYLLINE

SOLUTION; ORAL
CHOLEDYL
@ PARKE DAVIS 100MG/5ML N09268 012 NOV 27, 1984

SYRUP; ORAL
CHOLEDYL
PARKE DAVIS 50MG/5ML N09268 011
@ 50MG/5ML N09268 011

TABLET, DELAYED RELEASE; ORAL
CHOLEDYL
+ PARKE DAVIS 100MG N09268 003
+ 200MG N09268 007
@ 100MG N09268 003
@ 200MG N09268 007

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
DITROPAN
AA + HOECHST MARION RSSL **5MG/5ML** **N18211 001**
OXYBUTYNIN CHLORIDE
AA SILARX **5MG/5ML** **N74520 001** MAR 29, 1996

PAROXETINE HYDROCHLORIDE

TABLET; ORAL
PAXIL
@ SMITHKLINE BEECHAM EQ 10MG BASE N20031 001 DEC 29, 1992
+ EQ 30MG BASE N20031 003 DEC 29, 1992
@ EQ 40MG BASE N20031 005 DEC 29, 1992
EQ 10MG BASE N20031 001 DEC 29, 1992
EQ 30MG BASE N20031 003 DEC 29, 1992
+ EQ 40MG BASE N20031 005 DEC 29, 1992

PENTAMIDINE ISETHIONATE

POWDER FOR RECONSTITUTION; INHALATION
NEBUPENT
FUJISAWA 600MG/VIAL N19887 002 MAR 22, 1996

PENTOBARBITAL SODIUM

CAPSULE; ORAL
SODIUM PENTOBARBITAL
AA HALSEY **100MG** **N84677 001**
@ 100MG N84677 001

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON
AMARIC 2MG N20184 001 DEC 30, 1993
4MG N20184 002 DEC 30, 1993
+ 8MG N20184 003 DEC 30, 1993
RHONE POULENC RORER 2MG N20184 001 DEC 30, 1993
4MG N20184 002 DEC 30, 1993
+ 8MG N20184 003 DEC 30, 1993

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PHERAZINE VC
AA HALSEY **5MG/5ML;6.25MG/5ML** **N88868 001** MAR 02, 1987
@ 5MG/5ML;6.25MG/5ML N88868 001 MAR 02, 1987

PIROXICAM

CAPSULE; ORAL
PIROXICAM
AB DANBURY PHARMA **10MG** **N74287 001** MAY 16, 1996

PIROXICAM

CAPSULE; ORAL
PIROXICAM

AB	DANBURY PHARMA	20MG	N74287 002	MAY 16, 1996
> ADD > AB	ZENITH GOLDLINE	10MG	N74148 001	JUN 03, 1996
> ADD > AB		20MG	N74148 002	JUN 03, 1996

POLYESTRADIOL PHOSPHATE

INJECTABLE; INJECTION
ESTRADURIN

+	WYETH AYERST	40MG/AMP	N10753 001
@		40MG/AMP	N10753 001

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

AB	BIOCRAFT	8MEQ	N73531 001	APR 26, 1996
AB		10MEQ	N73532 001	APR 26, 1996

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

AP	FUJISAWA	2MEQ/ML	N87787 001	APR 20, 1982
@		2MEQ/ML	N87787 001	APR 20, 1982

PREDNISOLONE

SYRUP; ORAL
PRELONE

	MURO	5MG/5ML	N89654 001	JAN 17, 1989
		15MG/5ML	N89081 001	FEB 04, 1986
+		5MG/5ML	N89654 001	JAN 17, 1989
+		15MG/5ML	N89081 001	FEB 04, 1986

PREDNISOLONE ACETATE

SUSPENSION; OPHTHALMIC
PRED FORTE

BX +	ALLERGAN	1%	N17011 001

SUSPENSION/DROPS; OPHTHALMIC
PRED FORTE

AB +	ALLERGAN	1%	N17011 001

PREDNISONE

TABLET; ORAL
PREDNISONE

AB	SUPERPHARM	5MG	N88865 001 OCT 25, 1984
AB		10MG	N88866 001 OCT 25, 1984
AB		20MG	N88867 001 OCT 25, 1984
@		5MG	N88865 001 OCT 25, 1984
@		10MG	N88866 001 OCT 25, 1984
@		20MG	N88867 001 OCT 25, 1984

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PROCANBID

+	PARKE DAVIS	500MG	N20545 001 JAN 31, 1996
+		1GM	N20545 002 JAN 31, 1996

PROMAZINE HYDROCHLORIDE

TABLET; ORAL
SPARINE

	WYETH AYERST	50MG	N10348 002
+		100MG	N10348 003
+		50MG	N10348 002
@		100MG	N10348 003

PROPANTHELINE BROMIDE

TABLET; ORAL

			PRO-BANTHINE			
> DLT >	AA	+	ROBERTS LABS	7.5MG	N08732 003	
> DLT >	AA	+		15MG	N08732 002	
> ADD >	BP	+		7.5MG	N08732 003	
> ADD >	BP	+		15MG	N08732 002	
			PROPANTHELINE BROMIDE			
> DLT >	AA		PAR PHARM	15MG	N88377 001	
> DLT >					DEC 08, 1983	
> ADD >	BP			15MG	N88377 001	
> ADD >					DEC 08, 1983	
> DLT >	AA		ROXANE	7.5MG	N80927 001	
> DLT >	AA			15MG	N80927 002	
> ADD >	BP			7.5MG	N80927 001	
> ADD >	BP			15MG	N80927 002	

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

		PROPHENE 65			
AA		HALSEY	65MG	N83538 002	
	@		65MG	N83538 002	

PROPYLTHIOURACIL

TABLET; ORAL

		PROPYLTHIOURACIL			
BD		HALSEY	50MG	N80015 001	
	@		50MG	N80015 001	

PROTIRELIN

INJECTABLE; INJECTION

		THYPINONE			
AP	+	ABBOTT	0.5MG/ML	N17638 001	
	@		0.5MG/ML	N17638 001	
		THYREL TRH			
AP		FERRING LABS	0.5MG/ML	N18087 001	
	+		0.5MG/ML	N18087 001	

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		NOVAFED			
> DLT >	+	DOW PHARM	120MG	N17603 001	
> ADD >	+	HOECHST MARION RSSL	120MG	N17603 001	

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

		QUINIDINE GLUCONATE			
AB		HALSEY	324MG	N89476 001	
				APR 10, 1987	
	@		324MG	N89476 001	
				APR 10, 1987	

QUINIDINE SULFATE

CAPSULE; ORAL

		CIN-QUIN			
AB		SOLVAY	200MG	N85296 001	
			300MG	N85297 001	
			200MG	N85296 001	
	+		300MG	N85297 001	
		QUINIDINE SULFATE			
AB	+	LILLY	200MG	N85103 001	
	@		200MG	N85103 001	

TABLET; ORAL

		QUINIDINE SULFATE			
AB		1ST TX	200MG	N85068 001	
AB		BARR	200MG	N84177 001	
	@		200MG	N84177 001	
AB		HALSEY	200MG	N83583 001	
	@		200MG	N83583 001	
AB	+	LILLY	200MG	N85038 001	
	@		200MG	N85038 001	
AB		ROXANE	200MG	N83640 001	
AB	+		200MG	N83640 001	
AB			300MG	N85632 001	
AB	+		300MG	N85632 001	
	@	SCHERER	200MG	N85068 001	
		QUINORA			
AB	+	KEY PHARMS	300MG	N85222 001	
	@	SCHERING	300MG	N85222 001	

RAMIPRIL

CAPSULE; ORAL			
ALTACE			
HOECHST MARION RSSL	1.25MG	N19901 001	JAN 28, 1991
	2.5MG	N19901 002	JAN 28, 1991
	5MG	N19901 003	JAN 28, 1991
+	10MG	N19901 004	JAN 28, 1991
HOECHST ROUSSEL	1.25MG	N19901 001	JAN 28, 1991
	2.5MG	N19901 002	JAN 28, 1991
	5MG	N19901 003	JAN 28, 1991
+	10MG	N19901 004	JAN 28, 1991

RISPERIDONE

> ADD > SOLUTION; ORAL			
> ADD > RISPERDAL			
> ADD > + JANSSEN	1MG/ML	N20588 001	JUN 10, 1996
> ADD >			

RITONAVIR

CAPSULE; ORAL			
NORVIR			
+ ABBOTT	100MG	N20680 001	MAR 01, 1996
SOLUTION; ORAL			
NORVIR			
ABBOTT	80MG/ML	N20659 001	MAR 01, 1996

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL			
ELDEPRYL			
+ SOMERSET	5MG	N20647 001	MAY 15, 1996

SELEGILINE HYDROCHLORIDE

TABLET; ORAL			
ELDEPRYL			
+ SOMERSET	5MG	N19334 001	JUN 05, 1989
@	5MG	N19334 001	JUN 05, 1989

SERTRALINE HYDROCHLORIDE

TABLET; ORAL			
ZOLOFT			
PFIZER	EQ 25MG BASE	N19839 005	MAR 06, 1996

SODIUM PHENYLBUTYRATE

POWDER; ORAL			
BUPHENYL			
+ UCYCLYD	3GM/TEASPOONFUL	N20573 001	APR 30, 1996
TABLET; ORAL			
BUPHENYL			
+ UCYCLYD	500MG	N20572 001	MAY 13, 1996

SPIRAPRIL HYDROCHLORIDE

TABLET; ORAL			
RENORMAX			
SANDOZ	3MG	N20240 001	DEC 29, 1994
	6MG	N20240 002	DEC 29, 1994
	12MG	N20240 003	DEC 29, 1994
+	24MG	N20240 004	DEC 29, 1994
@ SCHERING	3MG	N20240 001	DEC 29, 1994
@	6MG	N20240 002	DEC 29, 1994
@	12MG	N20240 003	DEC 29, 1994

SPIRAPRIL HYDROCHLORIDE

TABLET; ORAL
RENORMAX
@ SCHERING — 24MG — N20240 004 DEC 29, 1994 — >_DLT_>

SUCRALFATE

TABLET; ORAL
CARAFATE
AB + BLUE RIDGE — **1GM** — **N18333 001** — >_DLT_>
SUCRALFATE
AB BIOCRAFT — **1GM** — **N70848 001** MAR 29, 1996 — >_ADD_>

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET; ORAL
SULFATRIM-DS
AB SUPERPHARM — **800MG;160MG** — **N70066 001** JUN 24, 1985 — >_DLT_>
@ — 800MG;160MG — N70066 001 JUN 24, 1985 — >_DLT_>
SULFATRIM-SS
AB SUPERPHARM — **400MG;80MG** — **N70065 002** JUN 24, 1985 — >_DLT_>
@ — 400MG;80MG — N70065 002 JUN 24, 1985 — >_DLT_>

TAMOXIFEN CITRATE

TABLET; ORAL
NOLVADEX
@ ZENECA — EQ 20MG BASE — N17970 002 MAR 21, 1994 — >_DLT_>
+ — EQ 20MG BASE — N17970 002 MAR 21, 1994 — >_DLT_>

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION
MYOVIEW
MEDI PHYSICS — N/A — N20372 001 FEB 09, 1996 — >_DLT_>

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL
HYTRIN
@ ABBOTT — EQ 1MG BASE — N19057 001 AUG 07, 1987 — >_DLT_>
@ — EQ 2MG BASE — N19057 002 AUG 07, 1987 — >_DLT_>
@ — EQ 5MG BASE — N19057 003 AUG 07, 1987 — >_DLT_>
@ — EQ 10MG BASE — N19057 004 AUG 07, 1987 — >_DLT_>
EQ 1MG BASE — N19057 001 AUG 07, 1987 — >_ADD_>
+ — EQ 2MG BASE — N19057 002 AUG 07, 1987 — >_ADD_>
EQ 5MG BASE — N19057 003 AUG 07, 1987 — >_ADD_>
EQ 10MG BASE — N19057 004 AUG 07, 1987 — >_ADD_>

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL
LAMISIL
+ SANDOZ — EQ 250MG BASE — N20539 001 MAY 10, 1996

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL
AB SUPERPHARM — **250MG** — **N62540 001** MAR 21, 1985
AB — **500MG** — **N62540 002** MAR 21, 1985
@ — 250MG — N62540 001 MAR 21, 1985
@ — 500MG — N62540 002 MAR 21, 1985

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION
THALLOUS CHLORIDE TL 201
MEDI PHYSICS — 2mCi/ML — N18110 001 FEB 01, 1982

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION
THALLOUS CHLORIDE TL 201

	MEDI PHYSICS	1mCi/ML	N18110 002	FEB 27, 1996

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
THEOVENT

BC	SCHERING	125MG	N87010 001	JAN 31, 1985
BC		250MG	N87910 001	JAN 31, 1985
	@	125MG	N87010 001	JAN 31, 1985
	@	250MG	N87910 001	JAN 31, 1985

INJECTABLE; INJECTION
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	**40MG/100ML**	**N19083 001**	NOV 07, 1984
	@	40MG/100ML	N19083 001	NOV 07, 1984

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	**80MG/100ML**	**N19083 002**	NOV 07, 1984
	@	80MG/100ML	N19083 002	NOV 07, 1984

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	**160MG/100ML**	**N19083 003**	NOV 07, 1984
	@	160MG/100ML	N19083 003	NOV 07, 1984

TABLET, EXTENDED RELEASE; ORAL
UNI-DUR

BC	+ KEY PHARMS	600MG	N89823 001	JAN 04, 1995

UNIPHYL

BC	PURDUE FREDERICK	600MG	N40086 001	APR 15, 1996

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HCL

AP	SANOFI WINTHROP	**100MG/ML**	**N40079 001**	MAY 03, 1996

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
MELLARIL

AA	SANDOZ	**30MG/ML**	**N11808 012**	
AA	+	30MG/ML	N11808 012	
AA		**100MG/ML**	**N11808 018**	
AA	+	100MG/ML	N11808 018	

TABLET; ORAL
THIORIDAZINE HCL

AB	SUPERPHARM	**10MG**	**N89103 001**	JUL 02, 1985
AB		**25MG**	**N89104 001**	JUL 02, 1985
AB		**50MG**	**N89105 001**	JUL 02, 1985
	@	10MG	N89103 001	JUL 02, 1985
	@	25MG	N89104 001	JUL 02, 1985
	@	50MG	N89105 001	JUL 02, 1985

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC
AKTOB

AT	AKORN	**0.3%**	**N64096 001**	JAN 31, 1996

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

AB	BARR	**100MG**	**N70162 001**	JAN 14, 1986
AB		**250MG**	**N70163 001**	JAN 14, 1986

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE

AB		BARR	500MG	N70164 001 JAN 14, 1986
	@		100MG	N70162 001 JAN 14, 1986
	@		250MG	N70163 001 JAN 14, 1986
	@		500MG	N70164 001 JAN 14, 1986
AB		ZENITH GOLDLINE	100MG	N18894 001 NOV 02, 1984
AB			250MG	N18894 002 NOV 02, 1984
AB			500MG	N18894 003 NOV 02, 1984
AB		ZENITH LABS	100MG	N18894 001 NOV 02, 1984
AB			250MG	N18894 002 NOV 02, 1984
AB			500MG	N18894 003 NOV 02, 1984

TOLBUTAMIDE

TABLET; ORAL
ORINASE

	@	PHARMACIA AND UPJOHN	500MG	N10670 001
AB	+	UPJOHN	500MG	N10670 001
		TOLBUTAMIDE		
AB		BARR	500MG	N87121 001
	@		500MG	N87121 001
AB		EON LABS	500MG	N12678 001
AB	+		500MG	N12678 001
AB		SUPERPHARM	500MG	N88893 001 NOV 19, 1984
	@		500MG	N88893 001 NOV 19, 1984

TOLMETIN SODIUM

TABLET; ORAL
TOLMETIN SODIUM

AB	BAKER NORTON	EQ 600MG BASE	N74399 001 MAR 28, 1996

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
HYCAMTIN

+	SMITHKLINE BEECHAM	EQ 4MG BASE/VIAL	N20671 001 MAY 28, 1996

TRANDOLAPRIL

TABLET; ORAL
MAVIK

	KNOLL PHARM	1MG	N20528 001 APR 26, 1996
		2MG	N20528 002 APR 26, 1996
+		4MG	N20528 003 APR 26, 1996

TRETINOIN

CREAM; TOPICAL
RENOVA

JOHNSON RW	0.05%	N19963 001 DEC 29, 1995

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL
ARISTOCORT A

AT		LEDERLE	0.5%	N80745 003
AT	+	LEDERLE LABS	0.5%	N80745 003
		KENALOG		
AT	+	APOTHECON	0.5%	N83944 001
	@		0.5%	N83944 001

SPRAY, METERED; NASAL
NASACORT AQ

+	RHONE POULENC RORER	0.055MG/INH	N20468 001 MAY 20, 1996

TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
TRIPROLIDINE HCL

HALSEY	1.25MG/5ML	N88735 001 JAN 17, 1985

TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
TRIPROLIDINE HCL
@ HALSEY — 1.25MG/5ML — N88735 001 JAN 17, 1985

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VERELAN
+ ELAN PHARM — 360MG — N19614 004 MAY 10, 1996

TABLET; ORAL
VERAPAMIL HCL
AB SIDMAK LABS NJ — **40MG** — **N72751 001** FEB 23, 1996

TABLET, EXTENDED RELEASE; ORAL
COVERA-HS
BC SEARLE — 180MG — N20552 001 FEB 26, 1996
BC — 240MG — N20552 002 FEB 26, 1996

VERAPAMIL HCL
AB MYLAN — **240MG** — **N74587 001** MAR 23, 1996
AB SIDMAK LABS NJ — **240MG** — **N72922 001** MAR 01, 1996

VIDARABINE

INJECTABLE; INJECTION
VIRA-A
+ PARKE DAVIS — EQ 187.4MG BASE/ML — N50523 001
@ — EQ 187.4MG BASE/ML — N50523 001

ASPIRIN

TABLET, EXTENDED RELEASE; ORAL

8-HOUR BAYER			
+ BAYER	650MG	N16030 001	
+ STERLING	650MG	N16030 001	
MEASURIN			
+ BAYER	650MG	N16030 002	
+ STERLING	650MG	N16030 002	

BROMPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

DIMETANE			
+ ROBINS AH	8MG	N10799 010 JUN 10, 1983	
+	12MG	N10799 011 JUN 10, 1983	
@ WHITEHALL ROBINS	8MG	N10799 010 JUN 10, 1983	
DIMETAPP			
+ WHITEHALL ROBINS	12MG	N10799 011 JUN 10, 1983	

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR; ORAL

DIMETAPP			
+ ROBINS AH	2MG/5ML;12.5MG/5ML	N13087 003 MAR 29, 1984	
+ WHITEHALL ROBINS	2MG/5ML;12.5MG/5ML	N13087 003 MAR 29, 1984	

TABLET, EXTENDED RELEASE; ORAL

DIMETAPP			
+ ROBINS AH	12MG;75MG	N12436 003 MAY 14, 1985	>ADD>
+ WHITEHALL ROBINS	12MG;75MG	N12436 003 MAY 14, 1985	>ADD>

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EFIDAC 24 PSEUDOEPHEDRINE HCL/BROMPHENIRAMINE MALEATE			
+ ALZA	16MG;240MG	N19672 001 MAR 29, 1996	>ADD>

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CODIMAL-L.A. 12			
CENT PHARMS	12MG;120MG	N18935 001 APR 15, 1985	
+	12MG;120MG	N18935 001 APR 15, 1985	
PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE			
+ CENT PHARMS	8MG;120MG	N19428 001 AUG 02, 1988	
PSEUDOEPHEDRINE HCL/CHLORPHENIRAMINE MALEATE			
+ GRAHAM	8MG;120MG	N18844 001 MAR 20, 1985	
+	12MG;120MG	N18843 001 MAR 18, 1985	
@	8MG;120MG	N18844 001 MAR 20, 1985	
@	12MG;120MG	N18843 001 MAR 18, 1985	
PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE			
CENT PHARMS	8MG;120MG	N19428 001 AUG 02, 1988	

IBUPROFEN

CAPSULE, ORAL

PROVEL			
+ SANDOZ	200MG	N20402 001 APR 20, 1995	
@ WHITEHALL ROBINS	200MG	N20402 001 APR 20, 1995	

SUSPENSION; ORAL

CHILDREN'S ADVIL			
WHITEHALL ROBINS	100MG/5ML	N20589 001 JUN 27, 1996	>ADD>

SUSPENSION/DROPS; ORAL

CHILDREN'S MOTRIN			
+ MCNEIL CONS PRODS	40MG/ML	N20603 001 JUN 10, 1996	>ADD>

TABLET; ORAL

IBUPROFEN			
HALSEY	200MG	N71027 001 SEP 29, 1987	>ADD>

IBUPROFEN

TABLET; ORAL
IBUPROFEN

	@ HALSEY	200MG	N71027 001 SEP 29, 1987
	@ LEMMON	200MG	N73141 001 MAY 29, 1992
> DLT >	MCNEIL CONS PRODS	200MG	N73019 001 MAR 30, 1994
> DLT >			
> ADD >	+	200MG	N73019 001 MAR 30, 1994
> ADD >			
	TAG PHARMS	200MG	N73141 001 MAY 29, 1992
> ADD >	JUNIOR STRENGTH MOTRIN		
> ADD >	MCNEIL CONS PRODS	100MG	N20602 001 JUN 10, 1996
> ADD >			
	NUPRIN		
> DLT >	+ BRISTOL MYERS	200MG	N72035 001 FEB 16, 1988
> DLT >			
> ADD >		200MG	N72035 001 FEB 16, 1988
> ADD >			

INSULIN PURIFIED BEEF

INJECTABLE; INJECTION
REGULAR ILETIN II

	+ LILLY	100 UNITS/ML	N18478 001
	@	100 UNITS/ML	N18478 001

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION
NOVOLIN N

	+ NOVO NORDISK	100 UNITS/ML	N19065 001 JAN 23, 1985
	@	100 UNITS/ML	N19065 001 JAN 23, 1985

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION
PROTAMINE ZINC INSULIN

	+ SQUIBB	40 UNITS/ML	N17928 001
	+	100 UNITS/ML	N17928 003
	@	40 UNITS/ML	N17928 001

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

INJECTABLE; INJECTION
PROTAMINE ZINC INSULIN

	@ SQUIBB	100 UNITS/ML	N17928 003

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF

INJECTABLE; INJECTION
ULTRALENTE

	+ NOVO NORDISK	100 UNITS/ML	N18385 001
	@	100 UNITS/ML	N18385 001

INSULIN ZINC SUSP PROMPT PURIFIED PORK

INJECTABLE; INJECTION
SEMILENTE

	+ NOVO NORDISK	100 UNITS/ML	N18382 001
	@	100 UNITS/ML	N18382 001

INSULIN ZINC SUSP PURIFIED BEEF

INJECTABLE; INJECTION
LENTE ILETIN II

	+ LILLY	100 UNITS/ML	N18477 001
	@	100 UNITS/ML	N18477 001

MICONAZOLE NITRATE

CREAM; VAGINAL
MICONAZOLE 7

	NMC	2%	N74164 001 MAR 29, 1996

MICONAZOLE NITRATE

	G AND W LABS	2%	N74366 001 FEB 22, 1996

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MONISTAT-3 COMBINATION PACK

	+ ADV CARE	2%,200MG	N20670 002 APR 16, 1996

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL (FOR MEN)			
BARRE	2%	N74588 001	APR 05, 1996
BAUSCH AND LOMB	2%	N74643 001	APR 09, 1996
COPLEY PHARM	2%	N74500 001	MAY 23, 1996
LEMMON	2%	N74589 001	APR 05, 1996
ROGAINE (FOR MEN)			
+ PHARMACIA AND UPJOHN	2%	N19501 002	FEB 09, 1996
ROGAINE (FOR WOMEN)			
+ PHARMACIA AND UPJOHN	2%	N19501 003	FEB 09, 1996

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS; OPHTHALMIC

OCUHIST			
AKORN	0.025%;0.3%	N20485 001	JAN 31, 1996
OPCON-A			
> DLT > + BAUSCH AND LOMB	0.027%;0.315%	N20065 001	JUN 08, 1994
> DLT >			
> ADD > +	0.02675%;0.315%	N20065 001	JUN 08, 1994
> ADD >			

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICORETTE			
+ SMITHKLINE BEECHAM	EQ 2MG BASE	N18612 002	FEB 09, 1996
+	EQ 4MG BASE	N20066 002	FEB 09, 1996

NIZATIDINE

TABLET; ORAL

AXID AR			
+ WHITEHALL ROBINS	75MG	N20555 001	MAY 09, 1996

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EFIDAC 24 PSEUDOEPHEDRINE HCL			
+ CIBA	240MG	N20021 002	DEC 15, 1992
EFIDAC/24			
+ CIBA	240MG	N20021 002	DEC 15, 1992

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 6 / JUN '96

NO JUNE 1996 APPROVALS

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS
[January 1, 1996 thru June 30, 1996]

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
Amphotericin B lipid complex TN= Abelcet	Treatment of invasive candidiasis.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=06/27/96 MA= / /
Amphotericin B lipid complex TN= Abelcet	Treatment of invasive zgomycosis.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=05/06/96 MA= / /
Amphotericin B lipid complex TN= Abelcet	Treatment of invasive coccidioidomycosis.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=05/06/96 MA= / /
Antihemophilic factor (human) TN= Alphanate	Treatment of von Willebrand's disease.	Alpha Therapeutic Corporation 5555 Valley Boulevard Los Angeles, CA 90032 DD=01/05/96 MA= / /
Arcitumomab TN= 99m Te-labeled CBA-Scan	Diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma.	Immunomedics, Inc. 300 American Road Morris Plains, NJ 07950 DD=05/10/96 MA= / /
Clostridial collagenase TN=	Treatment of advanced (involutional or residual stage) Dupuytren's disease.	Hurst, L. M.D. & Badalamente, M. Ph.D. State University of New York at Stony Brook School of Medicine Health Sciences Center T18-020 Stony Brook, NY 11794 DD=05/23/96 MA= / /
Collagenase (lyophilized) for injection TN= Plaquase	Treatment of Peyronie's disease.	Advance Biofactures Corporation 35 Wilbur Street Lynbrook, NY 11563 DD=03/12/96 MA= / /
Dihydrotestosterone TN=Androgel-DHT	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Unimed Pharmaceuticals, Inc. 2150 East Lake Cook Road, Suite 210 Buffalo Grove, IL 60089 DD=02/05/96 MA= / /
DMP 777 TN=	Therapeutic management of patients with lung disease attributable to cystic fibrosis.	Dupont Merck Pharmaceutical Company Dupont Merck Plaza, Maple Run 2110 Wilmington, DE 19805 DD=06/04/96 MA= / /
Etiocholanedione TN=	Treatment of Prader-Willi syndrome.	SuperGen, Inc. 3158 Des Plains Avenue Suite 10 Des Plains, IL 60018 DD=05/07/96 MA= / /
Gusperimus TN=Spanidin	Treatment of acute renal graft rejection episodes.	Bristol-Myers Squibb Company 5 Research Parkway P.O. Box 5100 Wallingford, CT 06492 DD=06/27/96 MA= / /
Indoxuridine TN=	Treatment of nonparenchymatous sarcomas.	NeoPharm, Inc. 225 East Deerpath, Suite 250 Lake Forest, IL 60045 DD=04/08/96 MA= / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
Interferon beta-1a TN=Rebif	Treatment of patients with secondary progressive multiple sclerosis.	Serono Laboratories, Inc. 100 Longwater Circle Norwell, MA 02061 DD=03/11/96 MA= / /
Lipid/DNA human cystic fibrosis gene TN=	Treatment of cystic fibrosis.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=04/08/96 MA= / /
Liposomal prostaglandin E1 injection TN=	Treatment of acute respiratory distress syndrome.	The Liposome Company, Inc. One Research Way Princeton, NJ 08540 DD=04/25/96 MA= / /
Methylnaltrexone TN=	Treatment of chronic opioid-induced constipation unresponsive to conventional therapy.	The University of Chicago 5841 South Maryland Avenue MC 4028 Chicago, IL 60637 DD=06/17/96 MA= / /
Nitazoxanide TN=	Treatment of cryptosporidiosis in HIV-positive and AIDS patients.	Unimed Pharmaceuticals, Inc. 2150 East Lake Cook Road, Suite 210 Buffalo Grove, IL 60089 DD=01/05/96 MA= / /
Rifapentine TN=	Prophylactic treatment of Mycobacterium avium complex in patients with acquired immunodeficiency syndrome and a CD4+count less than or equal to 75/mm3.	Marion Merrell Dow Inc. P.O. Box 9627 (Park A) Kansas City, MO 64137 DD=03/12/96 MA= / /
R-VIII SQ TN= REFACTO	For long-term and/or hospital treatment of hemophilia A or for treatment of patients with hemophilia A in connection with surgical procedures.	Pharmacia Inc. P.O. Box 16529 Columbus, OH 43216 DD=02/08/96 MA= / /
Somatropin for injection TN=Serostim	Treatment of children with AIDS-associated failure-to-thrive including AIDS-associated wasting.	Serono Laboratories, Inc. 100 Longwater Circle Norwell, MA 02061 DD=03/26/96 MA= / /
SU101 TN=	Treatment of ovarian cancer.	Sugen, Inc. 515 Galveston Drive Redwood City, CA 94063 DD=03/12/96 MA= / /
Testosterone TN=Androgel	Treatment of weight loss in AIDS patients with HIV-associated wasting.	Unimed Pharmaceuticals, Inc. 2150 East Lake Cook Road, Suite 210 Buffalo Grove, IL 60089 DD=02/05/96 MA= / /
Thalidomide TN=Synovir	Treatment of HIV-associated wasting syndrome.	Celgene Corporation P.O. Box 4914 7 Powder Horn Drive Warren, NJ 07059 DD=03/11/96 MA= / /
Uridine 5'triphosphate TN=VIL	To facilitate the removal of lung secretions in the treatment of patients with primary ciliary dyskinesia.	Inspire Pharmaceuticals, Inc. 4222 Emperor Boulevard, Suite 470 Durham, NC 27703 DD=06/26/96 MA= / /
Valine, isoleucine and leucine TN=VIL	Treatment of hyperphenylalaninemia.	Leas Research Products 4 Brookview Lane Troy, NY 12180 DD=01/05/96 MA= / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval

ORPHAN DRUG PRODUCT APPROVALS FOR 1996

Albendazole TN= Albenza	Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).	SmithKline Beecham Pharmaceuticals One Franklin Plaza P.O. Box 7929 Philadelphia, PA 19101 DD=01/17/96 MA=06/11/96
Albendazole TN= Albenza	Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and raccmose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis.	SmithKline Beecham Pharmaceuticals One Franklin Plaza P.O. Box 7929 Philadelphia, PA 19101 DD=01/18/96 MA=06/11/96
Bleomycin sulfate TN=Blenoxane	Treatment of malignant pleural effusion.	Bristol-Myers Squibb P.O. Box 4000 Princeton, NJ 08543 DD=09/17/93 MA=02/20/96
Corticorelin ovine triflutate TN=Acthrel	For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.	Ferring Laboratories, Inc. 400 Rella Boulevard, Suite 201 Suffern, NY 10901 DD=11/24/89 MA=05/23/96
Daunorubicin citrate liposome injection TN=DaunoXome	Treatment of patients with advanced HIV-associated Kaposi's sarcoma.	NeXstar Pharmaceuticals, Inc. 650 Cliffside Drive San Dimas, CA 91773 DD=05/14/93 MA=04/08/96
Ganciclovir intravitreal implant TN=Vitrasert Implant	Treatment of cytomegalovirus retinitis.	Chiron Vision 500 Iolab Drive Claremont, CA 91711 DD=06/07/95 MA=03/04/96
Interferon beta-1a TN=Avonex	Treatment of multiple sclerosis.	Biogen, Inc. 14 Cambridge Center Cambridge, MA 02142 DD=12/16/91 MA=05/17/96
Ofloxacin TN=Ocuflox Ophthalmic Solution	Treatment of bacterial corneal ulcers.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine, CA 92713 DD=04/18/91 MA=05/22/96
Respiratory syncytial virus immune globulin (human) TN=Respigam	Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV diesase.	MedImmune, Inc. 35 West Watkins Mill Road Gaithersburg, MD 20878 DD=09/27/90 MA=01/18/96
Sodium phenylutyrate TN=Buphenyl	Treatment of urea cycle disorders carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency	Ucyclyd Pharma 10819 Gilroy Road, Suite 100 Hunt Valley, MD 21031 DD=11/22/93 MA=04/30/96

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JUNE 1996 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 16TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

CLOZAPINE *IN VITRO* AND *IN VIVO* (TABLET)	NOV 15, 1995	APR 19, 1996

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 1-23, PARK BUILDING, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 16TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE CAPSULE; ORAL	325MG 50MG 40MG 10MG	95 P-0279/ CP1	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE CAPSULE; ORAL	325MG 50MG 40MG 7.5MG	95 P-0279/ CP2	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE CAPSULE; ORAL	500MG 50MG 40MG 10MG	95 P-0279/ CP3	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE CAPSULE; ORAL	500MG 50MG 40MG 7.5MG	95 P-0279/ CP4	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE TABLET; ORAL	325MG 50MG 40MG 10MG	95 P-0279/ CP1	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE TABLET; ORAL	325MG 50MG 40MG 7.5MG	95 P-0279/ CP2	MIKART	NEW COMBIANTION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08. 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE TABLET; ORAL	325MG 50MG 40MG 10MG	95 P-0279/ CP3	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08 1996
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; HYDROCODONE BITARTRATE TABLET; ORAL	325MG 50MG 40MG 7.5MG	95 P-0279/ CP4	MIKART	NEW COMBINATION NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 08, 1996
ACETAMINOPHEN; HYDROCODONE BITARTRATE CAPSULE; ORAL	325MG 5MG	95 P-0278/ CP1	MIKART	NEW STRENGTH	APPROVED MAY 28, 1996

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ACYCLOVIR SODIUM INJECTABLE; INJECTION	EQ 5MG BASE/ML (100ML/CONTAINER) (200ML/CONTAINER)	95 P-0268/ CP1	WILMER, CUTLER, & PICKERING	NEW DOSAGE FORM NEW STRENGTH	APPROVED FEB 27, 1996
ASPIRIN; BUTALBITAL CAPSULE; ORAL	650MG 50MG	96 P-0021/ CP1	SAVAGE	NEW DOSAGE FORM	APPROVED APR 19, 1996
ATRACURIUM BESYLATE INJECTABLE; INJECTION	0.5MG/ML 1MG/ML (100ML CONTAINER)	95 P-0372/ CP1	ABBOTT	NEW STRENGTH	APPROVED MAR 08, 1996
CARBIDOPA; LEVODOPA POWDER FOR RECONSTITUTION; ORAL	25MG/PACKET 100MG/PACKET	95 P-0100/ CP1	ATHENA	NEW DOSAGE FORM	APPROVED MAY 28, 1996
CARBIDOPA; LEVODOPA POWDER FOR RECONSTITUTION; ORAL	25MG/PACKET 250MG/PACKET	95 P-0100/ CP1	ATHENA	NEW DOSAGE FORM	APPROVED MAY 28, 1996
CHOLESTYRAMINE TABLET, CHEWABLE; ORAL	EQ 2GM RESIN	95 P-0277/ CP1	MAYRAND	NEW DOSAGE FORM NEW STRENGTH	APPROVED FEB 27, 1996
DILTIAZEM HYDROCHLORIDE INJECTABLE, INJECTION	5MG/ML (25ML/SYRINGE) (50ML/SYRINGE)	95 P-0196/ CP1	INTL MEDICATION	NEW STRENGTH	APPROVED FEB 27, 1996
EPINEPHRINE INJECTABLE; SUBCUTANEOUS	0.3MG/DELIVERY	95 P-0190/ CP1	SENETCK PLC	NEW ROUTE OF ADMINISTRATION	APPROVED FEB 15, 1996
HYDROCORTISONE BUTYRATE LOTION; TOPICAL	0.1%	95 P-0223/ CP1	MCKENNA & CUNEO	NEW DOSAGE FORM	APPROVED FEB 21, 1996
LACTULOSE CRYSTALS, FOR RECONSTITUTION; ORAL	20GM/PACKET	95 P-0287/ CP1	BENNETT	NEW DOSAGE FORM NEW STRENGTH	APPROVED APR 19, 1996
MEPERIDINE HYDROCHLORIDE INJECTABLE; INJECTION	10MG/ML (60ML/SYRINGE)	95 P-0348/ CP1	MALLINCKRODT	NEW STRENGTH	APPROVED MAR 08, 1996
METRONIDAZOLE LOTION; TOPICAL	0.75%	95 P-0328/ CP1	RNB PHARM	NEW DOSAGE FORM	APPROVED FEB 23, 1996
NIFEDIPINE CAPSULE, EXTENDED RELEASE; ORAL	30MG 60MG 90MG	95-P-0326/ CP1	KV	NEW DOSAGE FORM	APPROVED FEB 23, 1996
PACLITAXEL INJECTABLE; INJECTION	6MG/ML (16.7ML/VIAL) (33.3ML/VIAL) (50ML/VIAL)	95 P-0360/ CP1	ABBOTT	NEW STRENGTH	APPROVED APR 29, 1996

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 16TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-29 INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF THE CNS IN ADULTS
D-30 5000 IU DOSE FOR PHOPHYLAXIS AGAINST DEEP VEIN THROMBOSIS
D-31 CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
D-32 REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS

NEW INDICATION

I-141 TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
I-142 LOCALIZE MYOCARDIAL ISCHEMIA (REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
I-143 EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-144 ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
I-145 0.1MMOL/KG AS A SINGLE INTRAVENOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
I-146 CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS
I-147 PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
I-148 TREATMENT OF ACUTE PNEUMOCYSTIC CARINII PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE ($AaDO_2$) iS LESS THAN OR EQUAL TO 55 TORR
I-149 TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
I-150 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
I-151 PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
I-152 SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS
I-153 MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN]
I-154 PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
I-155 TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT
I-156 ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE

PATENT USE CODE

U-121 METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS
U-122 A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS
U-123 METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS
U-124 TREATMENT OF ACNE
U-125 TREATING NEUROGENERATIVE DISEASES
U-126 TREATMENT OF GASTRITIS
U-127 METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE
U-128 METHODS FOR TREATMENT OF TUMORS
U-129 METHOD TO DESTROY OR IMPAIR TARGET CELLS
U-130 MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS

EXCLUSIVITY TERMS

PATENT USE CODE

U-131	PHOTODAMAGED SKIN
U-132	INHIBITING HIV PROTEASE
U-133	MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET
U-134	TREATMENT OF ACNE VULGARIS
U-135	ANTITUMOR AGENT
U-136	PROCESS FOR WASTE NITROGEN REMOVAL
U-137	METHOD OF TREATING BACTERIAL VAGINOSIS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19806 001	ACRIVASTINE; SEMPREX-D	4650807	MAR 26, 2008	U-93		
	20338 001	ADAPALENE; DIFFERIN	4717720	APR 10, 2006	U-134	NCE	MAY 31, 2001
	20380 001	ADAPALENE; DIFFERIN	4717720	APR 10, 2006	U-134	NCE	MAY 31, 2001
>ADD>	20666 001	ALBENDAZOLE; ALBENZA				ODE	JUN 11, 2003
>ADD>						NCE	JUN 11, 2001
>ADD>	20298 001	ALLOPURINOL SODIUM; ZYLOPRIM				NDF	MAY 17, 1999
	20221 001	AMIFOSTINE; ETHYOL				I-149	MAR 15, 1999
>ADD>	19787 001	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007		I-156	JUN 14, 1999
>ADD>	19787 002	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007		I-156	JUN 14, 1999
>ADD>	19787 003	AMLODIPINE BESYLATE; NORVASC	4879303	MAR 25, 2007		I-156	JUN 14, 1999
	20541 001	ANASTROZOLE; ARIMIDEX	4935437	JUN 10, 2008			
	20428 001	AZELAIC ACID; AZELEX	4386104	MAY 31, 2000	U-124		
>ADD>	20075 001	BACLOFEN; LIORESAL				I-153	JUN 14, 1999
>ADD>	20075 002	BACLOFEN; LIORESAL				I-153	JUN 14, 1999
>ADD>	20469 001	BECLOMETHASONE DIPROPIONATE MONOHYDRATE; VANCENASE AQ				NP	JUN 26, 1999
	20498 001	BICALUTAMIDE; CASODEX	4636505	JAN 13, 2004			
	50443 001	BLEOMYCIN SULFATE; BLENOXANE				ODE	FEB 20, 2003
	19672 001	BROMPHENIRAMINE MALEATE; EFIDAC 24	4810502	MAR 14, 2006			
			4801461	MAR 14, 2006			
			4673405	MAR 18, 2003			
>ADD>			4662880	MAR 14, 2006		NP	MAR 29, 1999
	18731 001	BUSPIRONE HYDROCHLORIDE; BUSPAR	4182763	MAY 22, 2000	U-13		
			5015646	MAY 14, 2008			
	18731 002	BUSPIRONE HYDROCHLORIDE; BUSPAR	4182763	MAY 22, 2000	U-13		
			5015646	MAY 14, 2008			
	20421 001	BUTOCONAZOLE NITRATE; FEMSTAT 3	4078071	JUL 28, 1997			
						NP	DEC 21, 1998
	20273 001	CALCIPOTRIENE; DOVONEX	4866048	DEC 29, 2007	U-88	NCE	DEC 29, 1998
	20313 002	CALCITONIN, SALMON; MIACALCIN	4344949	OCT 03, 2000			
	18874 001	CALCITRIOL; CALCIJEX	4308264	JAN 28, 2001			
	18874 002	CALCITRIOL; CALCIJEX	4308264	JAN 28, 2001			
	18343 004	CAPTOPRIL; CAPOTEN				I-95	SEP 23, 1996
						I-101	JAN 28, 1997
	18343 007	CAPTOPRIL; CAPOTEN				I-95	SEP 23, 1996
						I-101	JAN 28, 1997
	20234 001	CARBAMAZEPINE; TEGRETOL-XR	5284662	FEB 08, 2011			
			RE34990	JUL 29, 2007			
	20234 002	CARBAMAZEPINE; TEGRETOL-XR	5284662	FEB 08, 2011			
			RE34990	JUL 29, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20234 003	CARBAMAZEPINE; TEGRETOL-XR	5284662	FEB 08, 2011			
			RE34990	JUL 29, 2007			
>ADD>	19880 001	CARBOPLATIN; PARAPLATIN	4140707	AUG 24, 1998			
>DLT>			~~4140707~~	~~AUG 25, 1998~~			
>ADD>	19880 002	CARBOPLATIN; PARAPLATIN	4140707	AUG 24, 1998			
>DLT>			~~4140707~~	~~AUG 25, 1998~~			
>ADD>	19880 003	CARBOPLATIN; PARAPLATIN	4140707	AUG 24, 1998			
>DLT>			~~4140707~~	~~AUG 25, 1998~~			
	19835 001	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358	JUN 25, 2002			
	19835 002	CETIRIZINE HYDROCHLORIDE; ZYRTEC	4525358	JUN 25, 2002			
>ADD>	20638 001	CIDOFOVIR; VISTIDE	5142051	AUG 25, 2009		NCE	JUN 26, 2001
	20398 001	CISAPRIDE MONOHYDRATE; PROPULSID	4962115	OCT 09, 2007	U-79	NCE	JUL 29, 1998
	20551 001	CISATRACURIUM BESYLATE; NIMBEX	5453510	SEP 26, 2012	U-127		
			4179507	DEC 18, 1996	U-127		
	20551 002	CISATRACURIUM BESYLATE; NIMBEX PRESERVATIVE FREE	5453510	SEP 26, 2012	U-127		
			4179507	DEC 18, 1996	U-127		
	20551 003	CISATRACURIUM BESYLATE; NIMBEX PRESERVATIVE FREE	5453510	SEP 26, 2012	U-127		
			4179507	DEC 18, 1996	U-127		
>ADD>	20340 001	CLOBETASOL PROPIONATE; TEMOVATE E				D-32	MAY 03, 1999
	20162 001	CORTICORELIN OVINE TRIFLUTATE; ACTHREL				NCE	MAY 23, 2001
	20479 001	CROMOLYN SODIUM; GASTROCROM	4515805	MAY 07, 2002	U-130		
			4421762	DEC 20, 2000	U-130		
	20287 001	DALTEPARIN SODIUM; FRAGMIN	4303651	JAN 04, 2005		NCE	DEC 22, 1999
						D-30	MAR 18, 1999
	20287 003	DALTEPARIN SODIUM; FRAGMIN	4303651	JAN 04, 2005		NCE	DEC 22, 1999
						D-30	MAR 18, 1999
	50704 002	DAUNORUBICIN CITRATE; DAUNOXOME				ODE	APR 08, 2003
	20118 001	DESFLURANE; SUPRANE	4762856	FEB 02, 2007	U-67	NCE	SEP 18, 1997
	19955 001	DESMOPRESSIN ACETATE; DDAVP	5047398	SEP 10, 2008			
	19955 002	DESMOPRESSIN ACETATE; DDAVP	5047398	SEP 10, 2008			
	20344 001	DEXFENFLURAMINE HYDROCHLORIDE; REDUX	4309445	JUN 16, 2000	U-133		
	20254 001	DICLOFENAC SODIUM; VOLTAREN-XR				NDF	MAR 08, 1999
	20092 001	DILTIAZEM HYDROCHLORIDE; DILACOR XR	5422123	JUN 06, 2012			
	20092 002	DILTIAZEM HYDROCHLORIDE; DILACOR XR	5422123	JUN 06, 2012			
	20092 003	DILTIAZEM HYDROCHLORIDE; DILACOR XR	5422123	JUN 06, 2012			
>ADD>	20401 001	DILTIAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013			
>ADD>	20401 002	DILTIAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013			
>ADD>	20401 003	DILTIAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013			
>ADD>	20401 004	DILTIAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	20401 005	DILTIAZEM HYDROCHLORIDE; TIAZAC	5529791	JUN 25, 2013		NS	SEP 11, 1998
	18723 001	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008		I-41	MAR 18, 1999
	18723 002	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008		I-41	MAR 18, 1999
	18723 003	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008		I-41	MAR 18, 1999
	20449 001	DOCETAXEL; TAXOTERE	4814470	JUL 14, 2007		NCE	MAY 14, 2001
>ADD>			5403858	JUL 03, 2012			
	20164 001	ENOXAPARIN SODIUM; LOVENOX	5389618	FEB 14, 2012			
			4692435	DEC 24, 2004	U-123		
			4486420	DEC 04, 2001	U-122		
	20472 001	ESTRADIOL; ESTRING				NDF	APR 26, 1999
	20457 001	ETOPOSIDE PHOSPHATE; ETOPOPHOS	5041424	AUG 20, 2008	U-135		
			4904768	FEB 27, 2007		NE	MAY 17, 1999
	20195 007	FENTANYL CITRATE; FENTANYL	4671953	JUN 09, 2004	U-87	NDF	OCT 04, 1996
	20548 001	FLUTICASONE PROPIONATE; FLOVENT	4335121	MAR 15, 2002		NP	MAR 27, 1999
	20548 002	FLUTICASONE PROPIONATE; FLOVENT	4335121	MAR 15, 2002		NP	MAR 27, 1999
	20548 003	FLUTICASONE PROPIONATE; FLOVENT	4335121	MAR 15, 2002		NP	MAR 27, 1999
>ADD>	20261 001	FLUVASTATIN SODIUM; LESCOL				D-31	MAR 20, 1999
>ADD>	20261 002	FLUVASTATIN SODIUM; LESCOL				D-31	MAR 20, 1999
	20235 001	GABAPENTIN; NEURONTIN	5084479	JAN 02, 2010	U-125		
			4894476	MAY 02, 2008			
			4087544	JAN 17, 2001	U-86	NCE	DEC 30, 1998
	20235 002	GABAPENTIN; NEURONTIN	5084479	JAN 02, 2010	U-125		
			4894476	MAY 02, 2008			
			4087544	JAN 17, 2001	U-86	NCE	DEC 30, 1998
	20235 003	GABAPENTIN; NEURONTIN	5084479	JAN 02, 2010	U-125		
			4894476	MAY 02, 2008			
			4087544	JAN 17, 2001	U-86	NCE	DEC 30, 1998
	20123 001	GADODIAMIDE; OMNISCAN	4687659	MAY 04, 2007		D-29	FEB 05, 1999
						I-145	FEB 05, 1999
						I-144	FEB 05, 1999
	19596 001	GADOPENTETATE DIMEGLUMINE; MAGNEVIST	4647447	MAR 03, 2004		I-146	FEB 28, 1999
	20569 001	GANCICLOVIR; VITRASERT				NP	MAR 04, 1996
	20509 001	GEMCITABINE HYDROCHLORIDE; GEMZAR				NCE	MAY 15, 2001
	20509 002	GEMCITABINE HYDROCHLORIDE; GEMZAR				NCE	MAY 15, 2001
	19726 001	GOSERELIN ACETATE; ZOLADEX	5366734	NOV 22, 2011			
			4767628	AUG 30, 2005		I-88	FEB 02, 1996
	20578 001	GOSERELIN ACETATE; ZOLADEX	5366734	NOV 22, 2011			
			4767628	AUG 30, 2005			
			4100274	APR 22, 1999		NP	JAN 11, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20239 001	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 29, 2007	U-89		
	20305 001	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 29, 2007	U-105		
	19836 001	HISTRELIN ACETATE; SUPPRELIN	4244946	JAN 13, 2000		NCE	DEC 24, 1996
	19836 002	HISTRELIN ACETATE; SUPPRELIN	4244946	JAN 13, 2000		NCE	DEC 24, 1996
	19836 003	HISTRELIN ACETATE; SUPPRELIN	4244946	JAN 13, 2000		NCE	DEC 24, 1996
>ADD>	20589 001	IBUPROFEN; CHILDREN'S ADVIL	4788220	JUL 08, 2007		NP	JUN 16, 1998
>ADD>	20602 001	IBUPROFEN; JUNIOR STRENGTH MOTRIN				NP	JUN 16, 1998
>ADD>	20603 001	IBUPROFEN; CHILDREN'S MOTRIN				NP	JUN 16, 1998
	20685 001	INDINAVIR SULFATE; CRIXIVAN	5413999	MAY 07, 2013	U-132	NCE	MAR 13, 2001
	20685 003	INDINAVIR SULFATE; CRIXIVAN	5413999	MAY 07, 2013	U-132	NCE	MAR 13, 2001
>ADD>	20563 001	INSULIN LISPRO; HUMALOG	5514646	MAY 07, 2013	U-111	NCE	JUN 14, 2001
	20351 001	IODIXANOL; VISIPAQUE 270	5349085	SEP 20, 2011		NCE	MAR 22, 2001
			4396597	JUL 03, 1999			
			4278654	JUL 03, 1999			
	20351 002	IODIXANOL; VISIPAQUE 320	5349085	SEP 20, 2011		NCE	MAR 22, 2001
			4396597	JUL 03, 1999			
			4278654	JUL 03, 1999			
>ADD>	20571 001	IRINOTECAN HYDROCHLORIDE; CAMPTOSAR	4604463	JUL 05, 2004		NCE	JUN 14, 2001
>ADD>	20083 001	ITRACONAZOLE; SPORANOX				I-155	SEP 28, 1998
	20564 001	LAMIVUDINE; EPIVIR	5047407	FEB 08, 2009			
	20596 001	LAMIVUDINE; EPIVIR	5047407	FEB 08, 2009			
	20241 001	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
	20241 002	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
	20241 003	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
	20241 004	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
	20241 005	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
	20241 006	LAMOTRIGINE; LAMICTAL	4602017	JUL 22, 2008	U-106	NCE	DEC 27, 1999
	20406 001	LANSOPRAZOLE; PREVACID	4689333	JUL 29, 2005	U-126	I-116	APR 08, 1999
	20406 002	LANSOPRAZOLE; PREVACID	4689333	JUL 29, 2005	U-126	I-116	APR 08, 1999
>ADD>	20597 001	LATANOPROST; XALATAN				NCE	JUN 05, 2001
	20517 001	LEUPROLIDE ACETATE; LUPRON DEPOT	5480656	JAN 02, 2013			
>ADD>	20219 001	LEVOCABASTINE HYDROCHLORIDE; LIVOSTIN	4369184	DEC 07, 2004		NCE	NOV 10, 1998
>DLT>			~~4369184~~	~~JAN 18, 2000~~			
	20575 001	LIDOCAINE; LIDOCAINE	5332576	JUL 26, 2011			
			5234957	FEB 27, 2011		NDF	MAY 21, 1999
	20575 002	LIDOCAINE; LIDOCAINE	5332576	JUL 26, 2011			
			5234957	FEB 27, 2011		NDF	MAY 21, 1999
	19558 001	LISINOPRIL; PRINIVIL				I-141	NOV 24, 1998
	19558 002	LISINOPRIL; PRINIVIL				I-141	NOV 24, 1998

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19558 003	LISINOPRIL; PRINIVIL				I-141	NOV 24, 1998
	19558 004	LISINOPRIL; PRINIVIL				I-141	NOV 24, 1998
	19558 006	LISINOPRIL; PRINIVIL				I-141	NOV 24, 1998
	19777 001	LISINOPRIL; ZESTRIL				I-141	NOV 24, 1998
	19777 002	LISINOPRIL; ZESTRIL				I-141	NOV 24, 1998
	19777 003	LISINOPRIL; ZESTRIL				I-141	NOV 24, 1998
	19777 004	LISINOPRIL; ZESTRIL				I-141	NOV 24, 1998
	19777 005	LISINOPRIL; ZESTRIL				I-141	NOV 24, 1998
	19940 001	MASOPROCOL; ACTINEX	4695590	APR 17, 2008			
>ADD>	20208 001	METRONIDAZOLE; METROGEL	5536743	JUL 16, 2013	U-137		
	20670 002	MICONAZOLE NITRATE; MONISTAT-3 COMBINATION PACK				NP	APR 16, 1999
>ADD>	20415 001	MIRTAZAPINE; REMERON				NCE	JUN 14, 2001
>ADD>	20415 002	MIRTAZAPINE; REMERON				NCE	JUN 14, 2001
	20312 001	MOEXIPRIL HYDROCHLORIDE; UNIVASC	4344949	OCT 03, 2000			
	19886 001	NAFARELIN ACETATE; SYNAREL	4234571	JUN 11, 2011			
	20353 001	NAPROXEN SODIUM; NAPRELAN				NDF	JAN 05, 1999
	20353 002	NAPROXEN SODIUM; NAPRELAN				NDF	JAN 05, 1999
	20353 003	NAPROXEN SODIUM; NAPRELAN				NDF	JAN 05, 1999
	20152 001	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003		NCE	DEC 22, 1999
	20152 002	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003		NCE	DEC 22, 1999
	20152 003	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003		NCE	DEC 22, 1999
	20152 004	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003		NCE	DEC 22, 1999
	20152 005	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003		NCE	DEC 22, 1999
	20152 006	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003		NCE	DEC 22, 1999
>ADD>	20636 001	NEVIRAPINE; VIRAMUNE	5366972	NOV 22, 2011		NCE	JUN 21, 2001
	20165 001	NICOTINE; NICODERM	5508038	APR 16, 2013			
	20165 002	NICOTINE; NICODERM	5508038	APR 16, 2013			
	20165 003	NICOTINE; NICODERM	5508038	APR 16, 2013			
	20385 001	NICOTINE; NICOTROL				NP	MAR 22, 1999
	20555 001	NIZATIDINE; AXID AR				NS	MAY 09, 1999
>ADD>	19921 001	OFLOXACIN; OCUFLOX				ODE	MAY 22, 2003
	19810 001	OMEPRAZOLE; PRILOSEC	4255431	APR 05, 2001	U-108	I-23	MAR 22, 1999
	19810 003	OMEPRAZOLE; PRILOSEC	4853230	APR 20, 2007	U-108	I-23	MAR 22, 1999
	20007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN				I-151	MAY 16, 1999
	18841 004	OXAPROZIN; DAYPRO				NCE	OCT 29, 1999*
	20031 001	PAROXETINE HYDROCHLORIDE; PAXIL				I-150	MAR 07, 1999
	20031 002	PAROXETINE HYDROCHLORIDE; PAXIL				I-150	MAR 07, 1999

* - In accordance with section 2105(c) of the FDA Export Reform and Enhancement Act of 1996 (Public Law 104-134)

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20031 003	PAROXETINE HYDROCHLORIDE; PAXIL				I-150	MAR 07, 1999
	20031 004	PAROXETINE HYDROCHLORIDE; PAXIL				I-150	MAR 07, 1999
	20031 005	PAROXETINE HYDROCHLORIDE; PAXIL				I-150	MAR 07, 1999
	19887 002	PENTAMIDINE ISETHIONATE; NEBUPENT				I-148	MAR 05, 1999
	20184 001	PERINDOPRIL ERBUMINE; ACEON	4508729	AUG 21, 2006			
	20184 002	PERINDOPRIL ERBUMINE; ACEON	4508729	AUG 21, 2006			
	20184 003	PERINDOPRIL ERBUMINE; ACEON	4508729	AUG 21, 2006			
	20451 001	PORFIMER SODIUM; PHOTOFRIN	5438071	AUG 01, 2012			
			5145863	JUN 12, 2007	U-129	ODE	DEC 27, 2002
			5028621	MAR 10, 2004			
			4932934	JUN 12, 2007	U-128	NCE	DEC 27, 2000
			4866168	MAR 10, 2004			
			4649151	MAR 10, 2004		ODE	DEC 27, 2002
>ADD>	19898 005	PRAVASTATIN SODIUM; PRAVACHOL	4346227	OCT 20, 2005		I-152	MAR 22, 1999
>ADD>			5030447	JUL 09, 2008			
>ADD>			5180589	JUL 09, 2008			
>ADD>	19898 006	PRAVASTATIN SODIUM; PRAVACHOL	4346227	OCT 20, 2005		I-152	MAR 22, 1999
			5030447	JUL 09, 2008			
			5180589	JUL 09, 2008			
>ADD>	19898 007	PRAVASTATIN SODIUM; PRAVACHOL	4346227	OCT 20, 2005		I-152	MAR 22, 1999
			5030447	JUL 09, 2008			
			5180589	JUL 09, 2008			
>ADD>	20279 001	PREDNICARBATE; DERMATOP				I-154	MAY 03, 1999
	20545 001	PROCAINAMIDE HYDROCHLORIDE; PROCANBID				NP	JAN 31, 1999
	20545 002	PROCAINAMIDE HYDROCHLORIDE; PROCANBID				NP	JAN 31, 1999
	19885 001	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4344949	OCT 03, 2002			
	19885 002	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4344949	OCT 03, 2002			
	19885 003	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4344949	OCT 03, 2002			
	19885 004	QUINAPRIL HYDROCHLORIDE; ACCUPRIL	4344949	OCT 03, 2002			
	19593 001	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	MAY 11, 2004			
			4521431	JUN 04, 2002	U-121		
			4128658	JUL 25, 1997	U-121		
	19593 002	RANITIDINE HYDROCHLORIDE; ZANTAC	4585790	MAY 11, 2004			
			4521431	JUN 04, 2002	U-121		
			4128658	JUL 25, 1997	U-121		
	20520 001	RANITIDINE HYDROCHLORIDE; ZANTAC 75	4880636	MAY 13, 2008			
			4521431	JUN 04, 2002	U-121		
			4128658	JUL 25, 1997	U-121		
	20272 001	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20272 002	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90		
	20272 003	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90		
	20272 004	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90		
	20272 005	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90		
>ADD>	20588 001	RISPERIDONE; RISPERDAL	4804663	DEC 29, 2007	U-90	NCE	DEC 29, 1998
	20659 001	RITONAVIR; NORVIR	5484801	JAN 28, 2014		NCE	MAR 01, 2001
	20680 001	RITONAVIR; NORVIR				NCE	MAR 01, 2001
	20628 001	SAQUINAVIR MESYLATE; INVIRASE	5196438	NOV 19, 2010			
>DEL>	~~19334 001~~	~~SELEGILINE HYDROCHLORIDE; ELDEPRYL~~	~~5242950~~	~~APR 23, 2012~~			
>DEL>			~~5151419~~	~~SEP 29, 2009~~			
>DEL>			~~4880833~~	~~NOV 14, 2006~~			
	20572 001	SODIUM PHENYLBUTYRATE; BUPHENYL	4457942	AUG 20, 2002	U-136	NCE	APR 30, 2001
	20573 001	SODIUM PHENYLBUTYRATE; BUPHENYL	4457942	AUG 20, 2002	U-136	NCE	APR 30, 2001
>ADD>						ODE	APR 30, 2003
	20280 004	SOMATROPIN, BIOSYNTHETIC; GENOTROPIN				NS	AUG 24, 1998
	20280 006	SOMATROPIN, BIOSYNTHETIC; GENOTROPIN				NS	AUG 24, 1998
	20240 001	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2003	U-3	NCE	DEC 29, 1999
	20240 002	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2003	U-3	NCE	DEC 29, 1999
	20240 003	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2003	U-3	NCE	DEC 29, 1999
	20240 004	SPIRAPRIL HYDROCHLORIDE; RENORMAX	4470972	SEP 11, 2003	U-3	NCE	DEC 29, 1999
	20412 001	STAVUDINE; ZERIT	4978655	JUN 25, 2008	U-94		
	20412 002	STAVUDINE; ZERIT	4978655	JUN 25, 2008	U-94		
	20412 003	STAVUDINE; ZERIT	4978655	JUN 25, 2008	U-94		
	20412 004	STAVUDINE; ZERIT	4978655	JUN 25, 2008	U-94		
	20412 005	STAVUDINE; ZERIT	4978655	JUN 25, 2008	U-94		
	20256 001	TECHNETIUM TC-99M BICISATE KIT; NEUROLITE	5279811	NOV 23, 2008	U-101	NCE	NOV 23, 1999
	19785 001	TECHNETIUM TC-99M SESTAMIBI KIT; CARDIOLITE				I-142	DEC 14, 1998
	20372 001	TECHNETIUM TC-99M TETROFOSMIN KIT; MYOVIEW	5045302	APR 10, 2007		NCE	FEB 09, 2001
	19057 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013	U-3		
	19057 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013	U-3		
	19057 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013	U-3		
	19057 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013	U-3		
	20347 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013			
	20347 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013			
	20347 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013			
	20347 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	5504207	APR 29, 2013			
	20539 001	TERBINAFINE HYDROCHLORIDE; LAMISIL	4755534	JUL 05, 2005	U-73	NDF	MAY 10, 1999
						NCE	DEC 30, 1999

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20489 001	TESTOSTERONE; ANDRODERM	5164190	NOV 17, 2008			
		5152997	OCT 06, 2009			
		4983395	JAN 08, 2009			
		4863970	SEP 05, 2006			
		4855294	AUG 08, 2006			
		4849224	JUL 18, 2006		NS	SEP 29, 1998
20671 001	TOPOTECAN HYDROCHLORIDE; HYCAMTIN	5004758	APR 02, 2008		NCE	MAY 28, 2001
20528 001	TRANDOLAPRIL; MAVIK				NCE	APR 26, 2001
20528 002	TRANDOLAPRIL; MAVIK				NCE	APR 26, 2001
20528 003	TRANDOLAPRIL; MAVIK				NCE	APR 26, 2001
19963 001	TRETINOIN; RENOVA	4877805	OCT 31, 2006	U-131		
		4603146	JUL 29, 2003	U-131	NP	DEC 29, 1998
19594 002	URSODIOL; ACTIGALL	4423041	DEC 27, 2000			
20487 001	VALACYCLOVIR HYDROCHLORIDE; VALTREX				I-147	MAR 29, 1999
20487 002	VALACYCLOVIR HYDROCHLORIDE; VALTREX				I-143	DEC 15, 1998
20151 001	VENLAFAXINE HYDROCHLORIDE; EFFEXOR				I-143	DEC 15, 1998
20151 002	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		NCE	DEC 28, 1998
20151 003	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		NCE	DEC 28, 1998
20151 004	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		NCE	DEC 28, 1998
20151 005	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		NCE	DEC 28, 1998
20151 006	VENLAFAXINE HYDROCHLORIDE; EFFEXOR	4535186	DEC 13, 2007		NCE	DEC 28, 1998
20552 001	VERAPAMIL HYDROCHLORIDE; COVERA-HS	4535186	DEC 13, 2007		NCE	DEC 28, 1998
		5190765	AUG 14, 2007			
		5160744	JUN 27, 2011			
		4753802	MAR 19, 2006			
		4252338	JUN 27, 2011		NP	FEB 26, 1999
20552 002	VERAPAMIL HYDROCHLORIDE; COVERA-HS	5190765	AUG 14, 2007			
		5160744	JUN 27, 2011			
		4753802	MAR 19, 2006			
		4252338	JUN 27, 2011		NP	FEB 26, 1999

*U.S. Government Printing Office: 1996 — 404-907/20013

New 16th Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

16TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7809

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $72.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature)

(10/95)

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(_____)_____
Daytime phone including area code

_____
Purchase Order No. (optional)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.